Archive for the ‘Genetic Testing’ Category

My wife and I can both roll our tongues but our son can't. I'm worried about his paternity (Photo: Shutterstock)

I am a 36-year-old woman and have no children, but I am planning on having some in a few years. Is it true that with advancing age I increase my chances of getting a child with Downs syndrome or cerebral palsy?

ALSO READ: Ask the doctor: Is penile enlargement surgery considered plastic surgery? Does it work?

Yes, these conditions have been associated with problematic pregnancies and abnormal foetal development. After age 35, older eggs tend to have abnormal cell division where the chromosomes may fail to separate in the correct way, leading to an excess number of expected chromosomes.

For example, in Downs syndrome, the foetus has an extra chromosome resulting in what is referred to as trisomy. Cerebral palsy is associated with complications of advanced parental age, especially the mothers. These may include miscarriages, multiple births, high blood pressure, gestational diabetes, and genetic mutations that impact brain development. Studies have also suggested that an older couple is more likely to use infertility procedures that can increase the risk of multiples and other risk factors.

I discovered that my fiances sister has albinism. How likely is it that any of our future children develops the condition?

There is a 50 percent chance your fiance is a carrier for the albinism gene. If this holds true, then there is a 25 percent chance that your future children may develop this condition.

My wife can roll her tongue (the rolling tongue gene). So can I. But our son, now 4, cant. I am worried about my childs paternity but dont want to stir the marriage yet. Do you think I should be worried or is there a genetic explanation?

There should be no cause to worry. More recent studies disputed the misleading assumption that leads to the conclusion that is worrying you. There was a study on identical twins who differed in their tongue-rolling trait, suggesting that the trait was not entirely under genomic influence as identical twins have the same genetic makeup.

I hope to get a child through a sperm bank. Do you think my request for physical characteristics of the sperm donor will help towards getting desirable traits in my future child?

ALSO READ: Why its better to have children before your 40s

Yes, most physical characteristics are easily inherited from parents to their offspring. However, this could be a mixture of traits from both the donor and the recipient.

How far is the world from genetically engineering desirable traits into people and consequently having designer babies?

It is already happening on a smaller scale for certain traits, for example women or men going to sperm banks look for super straights in their donors for IVF procedures.

The world is also moving towards precision medicine, or what is commonly known as personalised medicine where everyone has their medicine tailor-made to suit their genes and condition based on their genetic fingerprint.

With technologies such as CRISPR/Cas9 gene editing, the future of designer babies is possible although ethical considerations in human cloning restrict such practices and may fail to promote advancements in these technologies.

Can I influence my childrens personalities or are they predetermined before birth?

To some extent yes, but personality is influenced by various factors. One component may come from the genes and the other from environmental interactions. For example, exposure to different life circumstances greatly influences ones personality.

ALSO READ: Ask the doctor: How do I bring back the white colour of my child's discoloured teeth?

My four-year-old twins are very different. My son has a real mean streak. Hes always been like that. His sister is kind. I have been responsible for their upbringing so far. Are character traits in the genes?

The difference could be in their genetic makeup. As we know, we inherit half of our genes from each parent and different personality traits could arise from this. In addition, the contrast in their personality could emanate from their daily interactions with the external world, such as from observations.

For More of This Stories Subscribe to the Standard Epaper to get a copy of Eve Woman in the Standard

You also have not told us if you treat the children differently whereby in most cases girls are treated kindly with lots of pampering, which is thus reflected in their behaviour. Boys who are often groomed to harden up to face the real world like men and turn out as brave warriors.

As a geneticist, do you think psychopaths are born or made?

I think it is a mixed bag of fortunes here. Psychopaths could result from nature and nurture. Several studies have pointed to the existence of genetic abnormalities in psychopaths, whereas other cases have risen purely from their upbringing. For example, we have had cases of sociopathic behaviour arising after traumatic experiences and drug addiction.Couples can undergo genetic testing to determine if they have any conditions their children can inherit (Photo: Shutterstock)

I have read a bit about genetic testing for couples, and I am considering it before we start a family. My question is, if they find something worrying (my sister died of sickle cell anaemia) can it be prevented because we know beforehand?

It may not be prevented in its entirety, but may help in early management of the outcome. It may also help in decision making whether to proceed and have children in the full knowledge that they may develop an inherited condition from parents. For your case, you could be a carrier for sickle cell disease and this prepares you to seek genetic therapy such as stem cell transplants to correct the abnormal red (sickle) cells.

I did the BRCA gene test and I have the mutated gene. What are the chances I could get ovarian or breast cancer?

A mutated BRCA gene is only an indicator of higher risk of developing either ovarian or breast cancer. It does not mean that you already have the cancer. It helps you prepare to seek and make a plan for testing and monitoring of signs of the development of these cancers so that preventative or management measures can be instituted. This may help in following a lifestyle that can reduce the chances of accelerating the development of the disease.

Is there a genetic explanation as to why children, especially firstborns, look like their fathers?

Well, it is not always the case. Physical characteristics of the offspring sometimes might be a mixture of both the mothers and fathers characteristics. There are, however, extremes where a child may look like a copy of either parent. A child is a result of the union of genes of a mother and father, and the strength of expression of these genes may differ.

There is conflicting information out there about genetically modified foods. What are the facts and fiction on this?

Genetically modified foods refer to food items whose source material production, be it plant or animal, involves intentional mixing (manipulation) of genetic material not naturally found in the pure/natural breed.

The fuss brought about by anti-GMO campaigners has been related, in my opinion, to a lack of information. The genes being included have their function known from a science point of view. However, genes may interact and the results may not be known fully. How a gene will behave in the new organism is assumed to be what is known, but it does not rule out undesired effects. However, before a gene is used in GMO, experimental tests are usually performed to understand different scenarios under which it may elicit undesired effects.

Dr Fredrick Nindo, a geneticist, is a visiting post-doctoral research fellow at the Mediterranean Infection Institute for Research in Cancer and Ageing, France.

?

Do not miss out on the latest news. Join the Eve Digital Telegram channel HERE.

Visit link:
Ask the doctor: Is there a chance I am not my sons father? - The Standard

Breast Cancer Predictive Genetic Testing Market 2020, by Tools, Services, Business Application, Company Profiles, Trends, Demand and Investment Opportunities to 2026

A comprehensive and elaborate primary analysis on GlobalBreast Cancer Predictive Genetic TestingMarket report highlights numerous facts such as development factors, business enhancement strategies, statistical growth, financial status to help readers and clients to understand the market on a global scale. The market has uncovered rapid development in the current and past years and is going to progress with continuing development in the upcoming years. Overall, the study offers an in-depth overview of the worldwide market covering all major parameters. The study offers important statistics on the market status of producers and offers useful advice and direction for businesses and individuals interested in the industry. The research was provided for leading growth status, including developments, segmentation, landscape analysis, product types and applications. The industry report focuses on the growth opportunities, which will help the Global Breast Cancer Predictive Genetic Testing market to expand operations in the existing markets. The current Large Screen Splicing System market research report has demonstrated all the vital market growth factors and economic fluctuations mentioned owing to the immense attention gained in recent years.

Request for Sample Report @https://www.indexmarketsresearch.com/report/global-and-china-breast-cancer-predictive-genetic-testing-market/302630/#requestforsample

The report thoroughly describes and maps the Breast Cancer Predictive Genetic Testing Market with a flawless discernment on the existing situation of competition in the market. This will ultimately be helping investors as well as manufacturers if the industry, in better understanding the current and future directions, the Breast Cancer Predictive Genetic Testing Market will be headed in. This report also presents product specification, manufacturing process, and product cost structure, etc. Production is separated by regions, technology, and applications. Other important aspects that have been meticulously studied in the Breast Cancer Predictive Genetic Testing market report is Demand and supply dynamics, import and export scenario, industry processes and cost structures and major R&D initiatives. In the end, the report includes Breast Cancer Predictive Genetic Testing new project SWOT analysis, investment feasibility analysis, investment return analysis, and development trend analysis. In addition, the global Breast Cancer Predictive Genetic Testing market report delivers concise information about the federal regulations and policies that may indirectly affect market growth as well as the financial state. Further, the researchers have done the industry analysis to see the impact of numerous factors and understand the whole attractiveness of the industry. The market review helps to summaries the industrial and financial development within the industry through expert analysis. Later on, the report analyzes gross sales (volume & value), market share, market growth rate, market size on the basis of a variety of applications.

With the tables and figures, the Breast Cancer Predictive Genetic Testing market report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. The information available in the global Breast Cancer Predictive Genetic Testing market report is not only based on the facts but also on the case studies, which analysts have included to deliver appropriate information to the clients in a well-versed manner. The report also covers in-depth description, competitive scenario, wide product portfolio of prime players active in this market and business strategies adopted by competitors along with their SWOT analysis. The report also provides Porter analysis, PESTEL analysis and market attractiveness which helps to better understand the market scenario(macro and micro level). Some of these influences include annual revenue, key segments, production capacity and new products. Industry principles are also documented for market analysis. This is coupled with understanding business practices of the market, sympathetic governments presence in the industry, classifying leverage of Global Breast Cancer Predictive Genetic Testing market globally, reviewing commercial terms and conditions and analyzing market subjects and trends. The situation of the global market at the global and regional level is also described in the global Breast Cancer Predictive Genetic Testing market report through geographical segmentation.

Areas to be closely scrutinized for a clear understanding of the Breast Cancer Predictive Genetic Testing market inNorth America, Central and South America, Asia Pacific, Africa, Europe, India and others.This informative report involved some top-level manufacturers profiling. In this report, a comprehensive inquiry into the market has been completed. It consists of exams conducted on previous innovations, ongoing market conditions and future outlook.

Global Breast Cancer Predictive Genetic Testing Market Leading Players:Roche, Thermo Fisher Scientific, PerkinElmer, Quest Diagnostics, Myriad Genetics, Iverson Genetics, Cancer Genetics, OncoCyte Corporation, NeoGenomics, Invitae

Global Breast Cancer Predictive Genetic Testing Market Product Type:High Penetrant Genes, Intermediate Penetrant Genes, Low Penetrant Genes

Global Breast Cancer Predictive Genetic Testing Market Application Segment:Hospitals, Clinics, Others

Breast Cancer Predictive Genetic Testing Market Report Highlights The report provides a detailed analysis on current and future market trends to identify the investment opportunities Market forecasts till 2026, using estimated market values as the base numbers Key market trends across the business segments, Regions and Countries Key developments and strategies observed in the market Market Dynamics such as Drivers, Restraints, Opportunities and other trends In-depth company profiles of key players and upcoming prominent players Growth prospects among the emerging nations through 2026 Market opportunities and recommendations for new investments

This report provides pin-point analysis of Global Breast Cancer Predictive Genetic Testing Market:1. The report provides a forward-looking perspective on the global Breast Cancer Predictive Genetic Testing market historical data, status, and future forecast, production, revenue, consumption.2. It helps to identify rising trends, drivers, growth influencing factors in global Breast Cancer Predictive Genetic Testing market and regions.3. It provides full insights of market and in-depth analysis of market segments(by manufacturers, regions, types, and applications) to easily make business decisions.4. The report provides a 10-year forecast assessment of how the market is expected to grow in the future based on current and future market potential and advantages, opportunities and challenges.5. It helps to plan Business Strategies by understanding the rising trends shaping and enhancing Breast Cancer Predictive Genetic Testing market development.6. It helps to understand competitive developments such as expansions, acquisitions, agreements, and new product launches in the Breast Cancer Predictive Genetic Testing market.

Read Detailed Index Report @https://www.indexmarketsresearch.com/report/global-and-china-breast-cancer-predictive-genetic-testing-market/302630/

Analytical Tools:

The report offers exactly studied and analyzed data of the key industry players along with their share in the market. The analytical tools used during the research includes Porters five forces analysis, SWOT analysis, and investment feasibility and returns analysis. These vital tools are used to analyze the growth of the top vendors in the market.

Additionally, the Global Breast Cancer Predictive Genetic Testing Market report comprises the in-depth study of the market segmentation such as types and applications. However, sub-segments studying in this report are crucial for knowing the preference of the shifting market demands. Likewise, the research Global Breast Cancer Predictive Genetic Testing Market report provides the deep study of the sales medium channels, traders, dealers, distributors at global as well as local level. Moreover, the Global Breast Cancer Predictive Genetic Testing Market report

Finally, Overall data will help clients to make critical tactical business decisions as well as business planning and to know the scope of future developments. This report provides a competitive study, demand-side statistics for which we interview end-users and organize procedure surveys with the help of secondary research techniques, Breast Cancer Predictive Genetic Testing company reports, regulatory information, analytical techniques, Breast Cancer Predictive Genetic Testing production sales volume and expenditure statistics.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Request customize:-If you wish to find more details of the report or want a Customization Please contacts us. You can get a detailed of the entire research here.

Contact Us @sales@indexmarketsresearch.com

Read more from the original source:
Global Breast Cancer Predictive Genetic Testing Industry Developments & Assessment 2020-2026 : Roche,... - Azizsalon News

The global analytical report titled Genetic Testing market has been recently published by Market Research Inc to its expansive repository which helps to make informed decisions for business clients. The study includes a comprehensive analysis of this research report further also draws attention to historical records, existing market scenario and to future predictions of market growth.

Global competitors such as Genetic Testing are also highlighted in the study in order to get a stronger and effective outlook of the competition at domestic as well as global regions. The report further also offers comprehensive information based on primary and secondary research techniques to examine the data accurately

Request A sample copy of this Genetic Testing Market report at

https://www.marketresearchinc.com/request-sample.php?id=16612

The competitive landscape has been elaborated by profiling the leading key players

Abbott Laboratories, Bio-Rad Laboratories, Inc

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Genetic Testing Market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

The geographical segmentation includes study of global regions such as North America, Latin America, Asia-Pacific, Africa, and Europe. The report also draws attention to recent advancements in technologies and certain methodologies which further help to boost the outcome of the businesses. Furthermore, it also offers a comprehensive data of cost structure such as the cost of manpower, tools, technologies, and cost of raw material. The report is an expansive source of analytical information of different business verticals such as type, size, applications, and end-users.

Grab Your Report at an Impressive Discount

https://www.marketresearchinc.com/ask-for-discount.php?id=16612

Objectives of global Genetic TestingMarket:

The report also includes information on significant market players in order to deliver penetrative insights into the businesses with regards to successful strategies of top-notch companies. Moreover, the report offers comprehensive information of several traders by presenting accurate facts and figures of market shares.

It concludes by throwing light on the recent developments that took place in the Genetic Testing market and their influence on the future growth of this market.

Inquire more or share questions if any before the purchase on this report at

https://www.marketresearchinc.com/enquiry-before-buying.php?id=16612

About Us

Market Research Inc is farsighted in its view and covers massive ground in global research. Local or global, we keep a close check on both markets. Trends and concurrent assessments sometimes overlap and influence the other. When we say market intelligence, we mean a deep and well-informed insight into your products, market, marketing, competitors, and customers. Market research companies are leading the way in nurturing global thought leadership. We help your product/service become the best they can with our informed approach.

Contact:

Market Research Inc

Kevin

51 Yerba Buena Lane, Ground Suite,

Inner Sunset San Francisco, CA 94103, USA

Call Us: +1 (628) 225-1818

Write Us@sales@marketresearchinc.com

Here is the original post:
Genetic Testing Market Is Booming Across the Globe Explored in Latest Research with Top Key PlayersAbbott Laboratories, Bio-Rad Laboratories, Inc -...

BILLINGS Before the COVID-19 pandemic, way back in the 1300s there was a pestilence known as the Black Death, also called bubonic plague.

Estimated to have killed millions during several outbreaks, the bubonic plague is caused by a bacteria known as Yersinia pestis.

Although the new coronavirus pandemic has captured headlines and attention around the world over the past two months, bubonic plague has again reared its head, this time in the Greater Yellowstone Ecosystem. Recently published research by Mark Elbrock and his associates showed 47% of the 17 cougars that were captured and had their blood drawn in the southern GYE tested positive for exposure to the plague.

This suggests that: (1) Y. pestis may be present at higher levels in the GYE than previously assumed, Elbrock wrote in the Cambridge University Press, noting that the disease was also found in four of 11 mountain lions that were necropsied. His co-authors were Winston Vickers and Howard Quigley.

The study is not the first time that exposure to Y. pestis has been found in Greater Yellowstone Ecosystem cougars. In 2006, a study co-authored by Roman Biek and Toni Ruth, along with others, tested blood from 150 cougars collected over 15 years and found relatively low exposure to the bacteria less than 20%.

Ruth also found Yellowstone cougars in 2004 and 2005 that had succumbed to bubonic plague. When captured in the winter, they were infested with fleas. The animals died in the following summer.

Its a relatively common bacteria found in wildlife, more so in southern drier areas, said Dan Stahler, leader of the Yellowstone National Park Cougar Project.

The bacteria is commonly transmitted by fleas that infest rodents, everything from mice to ground squirrels. The cougars, along with other predators like coyotes, are exposed to the virus when they catch and eat infected animals.

Felines, including bobcats and lynxsee, tend to be more susceptible to Y. pestis than canines, Stahler said. For some reason, bears appear impervious to such infections, he added.

Being aware of contagions is why Stahler and his team approach any dead animal cautiously while conducting wildlife research.

Anyone in contact with animals needs to have such diseases at the forefront of their mind, he said.

Not to be fearful, or to panic, but its important to screen for it and be careful of it, he said.

In humans, bubonic plague causes enlarged lymph nodes in the armpits, groin and neck. It can also be accompanied by fever and muscle aches, along with other flu-like symptoms. Unlike COVID-19, it cant be transmitted from an infected person to others via respiratory droplets. Bubonic plague is also easily treated with a vaccine if caught soon enough.

According to Montana Fish, Wildlife and Parks website, detailed data on the distribution of plague in wildlife in Montana is not available, although it is believed to be present throughout the state. The most recent human case of plague in Montana was in 1992 when a hunter contracted the disease from a bobcat. In 1987, a hunter was infected after skinning an infected antelope.

Across the United States, only about seven people a year are infected, according to the Centers for Disease Control and Prevention. More prevalent in the Southwest, the United States saw spikes in human infections in 2006 and 2015, according to the CDC.

Prairie dogs are another species that is often infected by bubonic plague. In trying to reintroduce black-footed ferrets across the West, outbreaks of plague have repeatedly frustrated scientists efforts. Prairie dogs are the main food source for the ferrets, which also use the rodents dens as their living quarters.

The incidence of plague seems to increase in years with cooler summers that follow wet winters, Stahler said, possibly because those conditions are more conducive to flea survival.

Yellowstone National Parks cougar study continued this winter with the capture of seven cougars. Eight of the big cats are wearing GPS collars, allowing researchers to track their movements.

Soon-to-be published research based on a graduate students work on noninvasive genetic testing, like hair samples, is being used to provide insight to the parks cougar population. Stahler said the work shows that in the Northern Range of the park, which includes the Lamar Valley, there are about 35 to 45 cougars, a robust population.

The research team also continues to collect data via remote camera traps, which also will help with population estimates of the secretive animals. At one elk calf carcass, five lions were photographed feeding over several days.

We had one cool trigger where a mule deer went racing by and was then followed by a cougar, Stahler said.

Another series showed a whitetail deer racing past a camera near Hellroaring Creek, soon followed by a wolf. The wolf later walked back past the camera.

Unfortunately, the parks winter predator study was cut short in mid-March due to the coronavirus pandemic, Stahler said. Yellowstone National Park was closed to the public on March 23.

We decided to get our people home safely, he said.

View original post here:
Tale of bubonic plague in pumas revived by southern Yellowstone study - Sports and Weather Right Now

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Hereditary Testing market.

Trusted Business Insights presents an updated and Latest Study on Hereditary Testing Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Hereditary Testing market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Hereditary Testing Market Size, Market Research and Industry Forecast Report, 2020-2026 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Hereditary Testing Market

The global hereditary testing market size was valued at USD 5.8 billion in 2019 and is projected to register at a CAGR of 6.3% during the forecast period. The expanding reproductive genetic health space is one of the key market drivers. Key players, such as Natera, have reported a continuous increase in test volumes in womens health genetic testing for inherited conditions. This reflects the growing acceptance of hereditary tests among the population, thereby accelerating the revenue growth.Furthermore, a consistent rise in demand for newborn screening has led to an increase in sales of DNA testing kits. For instance, in November 2019, the Division of Consolidated Laboratory Services (DCLS) of the Virginia Department of General Services screened 7,868 newborns for nearly 31 hereditary and metabolic disorders. Increasing penetration of newborn screening across the globe is further aiding in the revenue growth.

Reforms in genetic testing guidelines have led to inclusion of multigene panel testing for hereditary cancer into clinical practice. The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast, ovarian, and colorectal cancers offers information on some of the cancer risk factors and management recommendations for single and multiple gene panels.Gradual developments in the distribution model is likely to benefit the genetic testing market. Technology providers are playing a crucial role in the market growth by improving their distribution service and increasing the efficiency of technology. Companies are using a cloud-based distribution model to make bioinformatics technology available for use by other laboratories. As of March, 2019, around 14 licensees were using Constellation software commercially for the marketing of Non-invasive Prenatal Testing (NIPT) products.Although these hereditary tests have huge advantages over conventional tests, several industry experts cited the cost and security concerns faced by consumers pertaining to the test. Moreover, lack of effective regulation of the tests is another key area that demands focused efforts. Despite these challenges, the genetic testing market is constantly expanding owing to the advantages of these innovative tests along with improved healthcare outcomes.DiseaseType Insights of Hereditary Testing Market

Product and service offerings with regard to various hereditary cancer testing continue to expand. Entry of major players, such as Quest, in this segment in the recent past, has significantly driven the hereditary testing market. Considering breast cancer genetic testing as a lucrative source of revenue, companies are focusing on business strategies to enhance their presence in this segment.One of the strategies is offering hereditary tests at a price lower than that offered by competitors. For instance, Color Genomics began selling its product for USD 259, whereas similar products offered by Myriad cost around USD 4,000. The increasing affordability of the tests is one of the key drivers of this segment. Furthermore, BRCA1 carriers have an 80% risk of developing breast cancer, which has also accelerated the developments in hereditary cancer testing market.

On the other hand, lung cancer is one of the major cancer forms that has a relatively few number of products. This is because most cases of lung cancer are not related to inherited genetic mutations. Similarly, for cervical cancer, most of the cases are caused by Human Papilloma Virus (HPV) and not genetic mutations. Lack of effective evidence over heritability of cervical cancer are driving the research activities in this market.Prenatal testing, irrespective of the associated risks, is increasingly gaining popularity. The cell-free DNA (cfDNA)-based NIPT testing is considered medically necessary by Anthem Blue Cross and Blue Shield of California. Previously, these players promoted cfDNA-based NIPT testing for trisomys 21, 18, and 13 only in high-risk pregnancies, as determined by maternal age and other factors.

Regional Insights of Hereditary Testing Market

Variations in regulatory frameworks pertaining to genetic tests across the world have significantly impacted the approval and commercialization of tests in the global market. Currently, a wide variety of genetic tests are being provided by several key companies in U.S. as well as several countries in Europe, Asia Pacific, and other regions.Europe accounted for the largest share in terms of revenue in 2019 and is likely to continue its dominance during the forecast period. This can be attributed to presence of key players providing genetic tests, high adoption of advanced treatments, and recommendations provided by government agencies to ensure the quality of hereditary testing services.In September 2019, Blueprint Genetics, a Finnish company, partnered with ARCHIMEDlife, a rare disease diagnostics company, to provide biochemical testing for rare diseases in North America. Through this partnership, both firms planned to diversify their range of genetic disease testing services to serve the customers better. Such initiatives are expected to strengthen the genetic testing scenario for hereditary disorders in North America, thereby accelerating regional revenue generation.

Market Share Insights of Hereditary Testing Market

Understanding the role of genetic mutation in disease occurrence has significantly accelerated the R&D in this market. Various retrospective studies are being carried out to understand the role of inherited mutations in disease pathology, which has led to key diagnostic developers, such as Quest Diagnostics, enter the market. Continuous authorizations and approvals of genetic tests by the government is expected to propel the organic revenue growth of operating companies.Some of the key players engaged in offering services and products in this market are Myriad Genetics, Inc.; Invitae Corporation; Illumina, Inc.; Natera, Inc.; Laboratory Corporation of America Holdings; F. Hoffmann-La Roche Ltd; Quest Diagnostics Incorporated; CooperSurgical, Inc.; Agilent Technologies, Inc.; Thermo Fisher Scientific, Inc.; Twist Bioscience; Sophia Genetics; Fulgent Genetic, Inc.; Medgenome; and CENTOGENE N.V.Furthermore, the expanding product portfolio is indicative of growing competition in the market. Each company is making focused efforts to offer products with competitive advantage. For example, cross-selling efforts by Natera helped the company witness lucrative revenue generation over the past years. The company promotes collective use of Horizon and Panorama products for women who have not undergone carrier screening tests in their first trimester.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Hereditary Testing Market Research ReportThis report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, this market research report has segmented the global hereditary testing market report on the basis of disease type and region:

Disease Type Outlook (Revenue, USD Million, 2019 2030)

Hereditary Cancer Testing

Lung Cancer

Breast Cancer

Colorectal Cancer

Cervical Cancer

Ovarian Cancer

Prostate Cancer

Stomach/Gastric Cancer

Melanoma

Sarcoma

Uterine Cancer

Pancreatic Cancer

Others

Hereditary Non-cancer Testing

Genetic Tests

Cardiac Diseases

Rare Diseases

Other Diseases

Newborn Genetic Screening

Preimplantation Genetic Diagnosis & Screening

Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests

Quick Read Table of Contents of this Report @ Hereditary Testing Market Size, Market Research and Industry Forecast Report, 2020-2026 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Read this article:
Hereditary Testing Market 2020: Global Industry Analysis By Size, Share, Growth, Trends And Forecast To 2026 - Cole of Duty

In the big leagues hes known as a dependable reliever.

Once a star pitcher at Wright State and now a stalwart of the Houston Astros bullpen, Joe Smith is awaiting the start of his 14th Major League Baseball season.

Hes appeared in 782 games and is known for his unique delivery, a cross between sidearm and submarine style.

But its his pitch off the mound even more so than on it thats especially impactful.

Were just trying to bring some good into the world, he told me the other day when discussing one of his charitable involvements.

Smith and his wife Allie LaForce the former Miss Teen USA, an Ohio University basketball player and journalism grad and now a TNT sideline reporter known for her coverage of the NBA and college basketball March Madness are the highest profile sports couple in the Miami Valley.

They live in Bellbrook in the offseason, though their careers have them travelling around the country much of the year.

At present theyre ensconced in West Palm Beach. Smith went to Florida for spring training and was joined by Allie when the COVID-19 pandemic shut down the sports world over two months ago.

Since then they have been doing some real relief work.

With the help of the Athletes and Causes, the nonprofit organization that runs their charitable ventures, they became the driving force of the Project FRONTLINE effort that has delivered over 15,000 meals from restaurants struggling through the coronavirus closures to over-taxed doctors, nurses and hospital staff.

Were just trying to say a little thank you to those people who are making sacrifices and risking their lives for the rest of us, Smith said. At the same time were getting local restaurants involved and giving them some revenue so hopefully they can pay some employees and keep their doors open.

While the couple made a considerable monetary commitment to the venture, they also got support from other pro athletes and celebrities people like fellow Astro Josh Reddick, former big leaguer Johnny Damon, Cleveland Cavalier Kevin Love, Portland Trailblazer CJ McCollum, Cleveland Indians manager Terry Francona, celebrity chef Michael Symon and others as well many everyday people.

Theyve helped hospitals in six states and especially in and around Houston and Cleveland, where Joe had two pitching stints and where Allie, who grew up some 40 miles away in Vermilion, once worked as a sports anchor and reporter at Fox affiliate, WJW Channel 8.

Their effort caught the imagination of many and spun off in some unlikely directions.

A woman from Oberlin called and said, I dont have a restaurant, but I have 1,000 orchid plants Id like to donate. Do you think nurses would want one? Allie said.

We had them shipped to our (Athletes and Causes) headquarters in Tampa and they gave them out. And we heard stories how some nurses were in tears knowing someone cared about them.

While immersed in this project, theyve continued work with their signature HelpCureHD Foundation.

The HD is for Huntingtons Disease, the congenital disorder that causes the progressive breakdown of nerve cells in the brain and erodes mental capacity and physical capability.

There is no cure and it is usually fatal.

Joes grandmother died from HD complications in 2006 and his mother, Lee, a former elementary school teacher in her early 60s, was diagnosed with it eight years ago and for the past 2 years has lived in an Alzheimers facility near Cincinnati.

Theres a 50 percent chance that Joe and his sister Megan could inherit the disease.

When he and Allie began the foundation, the goal was to raise awareness and provide financial backing for research. In recent years the focus has switched to helping families attempt costly in vitro fertilization with genetic testing that would help them end up with HD-free embryos to be implanted.

That not only would guarantee an HD-free child, but it would stop the devastating disease from continuing its generational chain.

They had planned to do the process themselves in April, but precautions against COVID-19 prevented those medical procedures. Thats made it especially tough this month since May is Huntingtons Disease Awareness Month.

They want to help families because the costs are steep. Smith said they already have spent $47,000 in their own attempt and it can be $8,000 with every doctors visit.

Were lucky because I play baseball, but few families can afford that, he said. And a lot of its not covered by insurance. Itd be emotionally devastating to know you couldnt help your child or future generations just because of finances.

He said HD is like a combination of Alzheimers, Parkinsons and ALS:

Its the Devils Disease.

A true love story

And yet something quite angelic has been happening, Allie said:

Joes dad cant get in to see Joes mom, so he sits outside of her window every single day just so she can see him. Hes an incredible man and its a true love story.

Joes mom really isnt talking anymore, but she gets up and sees him out there and they have lunch together.

Although she said Joes mom is losing her memory and motor skills, she likes those visits. Nurses will hold a phone up to her ear and Mike, her husband of 39 years, talks to her.

She always been her sons biggest fan and over the past couple of years the family has taped his night games and played them for her the next day.

That makes these days without baseball especially tough for her.

Allie said there were times when his moms condition first began to worsen that Joe struggled with being away from her to play baseball:

He got to a point where he was questioning: Why am I playing the game? He wasnt feeling any fulfillment at the core of himself.

But then when he found that our foundation could help families get HD-free babies and change a familys future, he realized the platform and the financial capabilities he had with baseball. He started to feel a new fulfillment. That made the game worth it again.

Smith said he knows some peoples beliefs dont allow them to go along with this and thats fine But for me, this is a chance to get rid of a terrible disease.

Youre not changing eye color or height or anything else about the human being. Youre just knocking the Huntingtons gene out.

They had 24 families in their program when the pandemic put everything on hold. But recently they got word that two families one in Ohio, one in Houston have HD-free pregnancies.

That was a really rewarding moment, Smith said. Thats what were trying to do here. Were just trying to bring some good into the world.

Giving back

With their round-the-calendar careers she covering basketball and football, he playing baseball Allie said these have been the first weekends theyve had off together since they married in 2015.

While she said it was awesome for their relationship, they were even more intent on looking out for others.

I think it has to do with both of our upbringings, she said. In my hometown, my parents would run steak fries to raise money if somebody in our high school or community was in need. I can remember working at them growing up.

And when I was Miss Teen USA, I was like 16 and went all over the country raising over $100 million for different charities.

Smith continues to embrace the Wright State program which he joined as a walk-on out of Amelia High School near Cincinnati. He became the Horizon League Pitcher of the Year and in 2006 was a third-round draft pick of the New York Mets.

His career took him to Cleveland, the Los Angeles Angels, Chicago Cubs, Toronto, back to Cleveland and in December of 2017 he signed with the Astros. He suffered a ruptured Achilles in a workout the following December and pitched just 25 innings in the latter part of last season, but still had a 1.80 era.

This past December, three months shy of 36, he re-signed for $8 million over two years.

He said he was impressed with the Astros from the start:

When I walked into that clubhouse in 2018, it was unbelievable. Everybody was looking for ways to give back to the community. A lot of it had to do with the way (Hurricane) Harvey hit the city (in 2017.) They understood what people were going through and tried to help anyway they could.

Now Project FRONTLINE which sent hundreds of meals to places like the Lyndon B. Johnson Hospital and Texas Childrens Hospital is continuing that communal embrace.

And if you want to donate to either Project FRONTLINE orHelpCureHD, go toathletesandcauses.org and follow the prompts.

Back to baseball?

As restrictions are being eased across the nation, preliminary talks have begun about baseballs return this season. Last week Major League Baseball presented a 67-page proposal to the Players Association that addressed some issues.

Its going to be different, but the feeling I get from everybody (players and management) is that they all want to get back on the field and start playing, Smith said. But there are so many questions to be answered:

Whats spring training going to look like? And the regular season? Where will teams play? What will travel be like? And then theres the economic issues.

And one thing cant be overlooked here. It takes a lot more than 25 young guys running around to play baseball.

We have four coaches who are 70 years old and technically in that high-risk category. There are trainers, front office people and so many others in that group, too. We need to keep them safe.

And weve got guys in our league who are literally taking care of their families. Some have 10 people living with them. Some have their parents living with them. God forbid, you bring the virus home because one of your teammates was careless.

But on the flip side, theres also a woman in her early 60s for whom hed certainly like to be back on the field.

For all her physical struggles and cognitive issues, his mom knows exactly what hes doing, Allie said:

She knows if he had a good game or a bad one. She knows how many batters he faced. How many strikeouts he got. She loves her son so much. She knows just what hes doing.

She knows his pitch.

She knows, in so many ways, he and his wife Allie are just trying to bring some good into the world.

Thank you for reading the Dayton Daily News and for supporting local journalism. Subscribers: log in for access to your daily ePaper and premium newsletters.

Thank you for supporting in-depth local journalism with your subscription to the Dayton Daily News. Get more news when you want it with email newsletters just for subscribers. Sign up here.

See original here:
Archdeacon: Trying to bring some good into the world - Dayton Daily News

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Direct-to-Consumer Genetic Testing market.

Trusted Business Insights presents an updated and Latest Study on Direct-to-Consumer Genetic Testing Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Direct-to-Consumer Genetic Testing market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Direct-to-Consumer Genetic Testing Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Abstract, Snapshot, Market Analysis & Market Definition: Direct-to-Consumer Genetic Testing MarketIndustry / Sector Trends

Direct-to-Consumer Genetic Testing Market size was valued at USD 831.5 million in 2018 and is expected to witness 15.2% CAGR from 2019 to 2025.

U.S. DTC Genetic Testing Market Size, By Test Type, 2018 & 2025 (USD Million)

Rising prevalence of genetic diseases such as cystic fibrosis and Alzheimers globally is one of the major factors fostering direct-to-consumer genetic testing market growth. According to Global Genes, over 300 million people globally suffer from rare diseases. Recently developed DTC genetic tests allows consumer to identify probability of acquiring a specific genetic disease. Therefore, increasing adoption of DTC genetic testing for early disease detection and identification of genetic diseases will boost the industry growth over forecast timeline.

Increasing demand for personalized medications to treat genetic diseases will positively impact industry growth in forthcoming years. Individuals genome must be tested to develop personalized medicines. This increases the demand for DTC genetic kits since, it provides detailed information about individuals genetic predisposition. As detailed information regarding genetic makeup of individuals is easily available with the use of DTC genetic kits, researchers can easily design and develop personalized medicine that would help in faster patient recovery. Aforementioned factor is expected to drive the industry growth. However, high cost of DTC genetic testing kits may hamper industry growth to some extent during the forecast period.

Market Segmentation, Outlook & Regional Insights: Direct-to-Consumer Genetic Testing Market

Direct-to-Consumer Genetic Testing Market, By Test Type

Predictive testing segment will experience around 17% growth throughout the analysis period. Considerable segmental growth can be associated with rising prevalence of genetic diseases. Recently developed DTC genetic tests help to identify mutations that increase the chances of acquiring specific disease accurately. Surging awareness regarding benefits of such presymptomatic testing has reduced the mortality rates by enabling effective management of disease. Above mentioned factors have stimulated the segmental growth that is predicted to continue over the forecast timeframe.

Ancestry and relationship testing segment accounted for over 43% revenue share in 2018. Increasing awareness regarding ethnicity tests amongst the American and European population has increased the demand for DTC genetic tests. Accuracy and efficiency possessed by these tests has fostered segmental growth. Moreover, ancestry tests developed by companies such as Ancestry.com are user friendly. Availability of robust DTC ancestry tests providing meaningful clinical, genealogical and even forensic information will positively impact the segment growth.

Direct-to-Consumer Genetic Testing Market, By Technology

Targeted analysis segment was valued over USD 310 million in 2018. Targeted analysis is utilized for determining the defects in genes that are responsible for a particular disorder. Targeted genotyping can accurately measure an individuals gene pool that encodes important information regarding various diseases. Targeted analysis can be conducted at significant low cost compared to other available techniques that should augment its adoption rate over forecast timeframe.

Single nucleotide polymorphism segment will experience around 15% growth throughout the forecast period. Single nucleotide polymorphism chips specifically detect changes in single nucleotide that increases the efficiency of tests. For instance, SNP chips utilized for diagnosing hereditary cancers have detected 1300 mutations in BRCA2 genes. Various companies such as Ancestry.com and Color Genomics utilize SNP arrays that analyse gene sequences at a specific resolution and reveal detailed analysis about the defective genes that may in future cause certain disease. Increasing adoption of such advanced SNP chips in DTC testing kits will trigger the segmental growth.

Germany DTC Genetic Testing Market Size, By Technology, 2018 (USD Million)

Direct-to-Consumer Genetic Testing Market, By Region

North America direct-to-consumer genetic testing market accounted for around 39% regional share in 2018. Regional market growth can be attributed to increasing prevalence of genetic diseases. Rare genetic diseases such as thalassemia, hemophilia and anaemia require continuous and critical monitoring. According to CDC, every year more than 1,000 people are affected by thalassemia. Furthermore, American population has higher literacy rate and also, awareness regarding DTC tests is high amongst the American population that augments demand for DTC genetic tests.

Europe is estimated to experience around 15% growth over the coming years. European direct-to-consumer genetic testing market is highly regulated and for carrying out some of the genetic tests through DTC kits, customers are required to have physicians prescription. However, currently, European regulatory bodies are working on improving regulations set on DTC tests due to improved accuracy and efficiency possessed by them. Thus, improvement in regulatory scenario will positively impact regional market growth.

Latin America DTC Genetic Testing Market Size, By Country, 2025 (USD Million)

Key Players, Recent Developments & Sector Viewpoints: Direct-to-Consumer Genetic Testing Market

Few of the eminent industry players operating in direct-to-consumer genetic testing market are Ancestry, 23andMe, Color, Family Tree DNA, EasyDNA, Helix, Identigene, Full Genomes, Genesis HealthCare, Karmagenes, MyHeritage, MapMyGenome, Living DNA and Pathway Genomics. Chief industry players implement numerous initiatives such as mergers, acquisitions and new product launch to maintain their market position. Receiving approvals from regulatory bodies for new products will also foster companys revenue share. For instance, in October 2018, 23andme received first U.S. FDA approval for de novotechnology utilized in pharmacogenomic tests. This approval will enable company to launch innovative products, thereby fostering companys growth.

Direct-to-Consumer (DTC) Genetic Testing Industry Viewpoint

Direct-to-consumer genetic testing industry can be traced back to early 2000s. Earlier DTC tests were thought to be convenient as they would allow the patients to access their genetic information without involvement of physician. Although, DTC genetic testing kits had several benefits, in the initial days, they were stringently regulated by regulatory bodies. Regulatory scenario has always been stringent since the introduction of DTC genetic kits in European countries. Currently, there has been change in the regulatory scenario and European countries have started receiving approval for DTC genetic kits. Defects in the DTC kits have been reduced and people have started relying on these kits. DTC genetic testing market is sort of matured in North America due to numerous technological advancements and is still in developing phase in Asian countries. With further advancements in technology, DTC genetic tests industry will experience numerous growth opportunitie

Key Insights Covered: Exhaustive Direct-to-Consumer Genetic Testing Market1. Market size (sales, revenue and growth rate) of Direct-to-Consumer Genetic Testing industry.2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Direct-to-Consumer Genetic Testing industry.3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Direct-to-Consumer Genetic Testing industry.4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Direct-to-Consumer Genetic Testing industry.

Research Methodology: Direct-to-Consumer Genetic Testing Market

Quick Read Table of Contents of this Report @ Direct-to-Consumer Genetic Testing Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

See the rest here:
Direct-to-Consumer Genetic Testing Market Analysis Of Global Trends, Demand And Competition 2020-2028 - Cole of Duty

Direct-To-Consumer Genetic Testing Market 2020 report share informative data figures as well as important insights regarding some of the market component which is considered to be future course architects for the market. This includes factors such as market size, market share, market segmentation, significant growth drivers, market competition, different aspects impacting economic cycles in the market, demand, expected business up-downs, changing customer sentiments, key companies operating in the Direct-To-Consumer Genetic Testing Market, etc. In order to deliver a complete understanding of the global market, the report also shares some of the useful details regarding regional as well as significant domestic markets. The report presents a 360-degree overview and SWOT analysis of the competitive landscape of the industries.

Top Key players of Direct-To-Consumer Genetic Testing Market Covered In The Report:AncestryColorEasyDNAFamily Tree DNAFull GenomesGenesis HealthCareHelixIdentigeneKarmagenesLiving DNAMapMyGenome. Key Market Segmentation of Direct-To-Consumer Genetic Testing:

Market by Test Type

(Ancestry & Relationship Testing, Carrier Testing, Predictive Testing, and Nutrigenomics Testing)

Technology

(Targeted Analysis, Single Nucleotide Polymorphism (SNP) Chips, and Whole Genome Sequencing (WGS))

Direct-To-Consumer Genetic Testing Market Region Mainly Focusing:

Europe Direct-To-Consumer Genetic Testing Market (Austria, France, Finland, Switzerland, Italy, Germany, Netherlands, Poland, Russia, Spain, Sweden, Turkey, UK), Asia-Pacific and Australia Direct-To-Consumer Genetic Testing Market (China, South Korea, Thailand, India, Vietnam, Malaysia, Indonesia, and Japan), The Middle East and Africa Direct-To-Consumer Genetic Testing Market (Saudi Arabia, South Africa, Egypt, Morocco, and Nigeria), Latin America/South America Direct-To-Consumer Genetic Testing Market (Brazil and Argentina), North America Direct-To-Consumer Genetic Testing Market (Canada, Mexico, and The USA)

Factors such as industry value chain, key consumption trends, recent patterns of customer behaviors, overall spending capacity analysis, market expansion rate, etc. The report also incorporates premium quality data figures associated with financial figures of the industry including market size (in USD), expected market size growth (in percentage), sales data, revenue figures and more. This might enable readers to reach quicker decisions with data and insights at hand.

Buy Full Report Now @ https://www.qurateresearch.com/report/buy/HnM/direct-to-consumer-genetic-testing-market/QBI-CMR-HnM-738584/

(A free report data (as a form of Excel Datasheet) will also be provided upon request along with a new purchase.)

Key Highlights from Direct-To-Consumer Genetic Testing Market Study:

Income and Sales Estimation Historical Revenue and deals volume is displayed and supports information is triangulated with best down and base up ways to deal with figure finish market measure and to estimate conjecture numbers for key areas shrouded in the Direct-To-Consumer Genetic Testing report alongside arranged and very much perceived Types and end-utilize industry. Moreover, macroeconomic factor and administrative procedures are discovered explanation in Direct-To-Consumer Genetic Testing industry advancement and perceptive examination.

Assembling Analysis The Direct-To-Consumer Genetic Testing report is presently broke down concerning different types and applications. The Direct-To-Consumer Genetic Testing market gives a section featuring the assembling procedure examination approved by means of essential data gathered through Industry specialists and Key authorities of profiled organizations.

Competition Analysis Direct-To-Consumer Genetic Testing Leading players have been considered relying upon their organization profile, item portfolio, limit, item/benefit value, deals, and cost/benefit.

Demand and Supply and Effectiveness Direct-To-Consumer Genetic Testing report moreover gives support, Production, Consumption and (Export and Import).

Major Points Covered in Table of Contents:

Direct-To-Consumer Genetic Testing Market OverviewMarket Competition by ManufacturersProduction Market Share by RegionsConsumption by RegionsGlobal Direct-To-Consumer Genetic Testing Production, Revenue, Price Trend by TypeGlobal Direct-To-Consumer Genetic Testing Market Analysis by ApplicationsCompany Profiles and Key Figures in Direct-To-Consumer Genetic Testing BusinessDirect-To-Consumer Genetic Testing Manufacturing Cost AnalysisMarketing Channel, Distributors, and CustomersMarket DynamicsGlobal Direct-To-Consumer Genetic Testing Market ForecastResearch Findings and ConclusionMethodology and Data Source

In a word, the Direct-To-Consumer Genetic Testing Market report provides major statistics on the state of the Direct-To-Consumer Genetic Testing industry with a valuable source of guidance and direction for companies and individuals interested in the market. At the end, Direct-To-Consumer Genetic Testing Market Report delivers a conclusion which includes Research Findings, Market Size Evaluation, Global Market Share, Consumer Needs along with Customer Preference Change, Data Source. These factors will raise the growth of the business overall.

Contact Us:

Web:www.qurateresearch.comE-mail:[emailprotected]Ph: US +13393375221

Note: In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Read more:
Direct-To-Consumer Genetic Testing Market 2020 | Covid19 Impact Analysis | Business Outlook, Growth, Revenue, Trends and Forecasts 2027 - Cole of Duty

The global Direct-To-Consumer (DTC) Genetic Testing market study encloses the projection size of the market both in terms of value (Mn/Bn US$) and volume (x units). With bottom-up and top-down approaches, the report predicts the viewpoint of various domestic vendors in the whole market and offers the market size of the Direct-To-Consumer (DTC) Genetic Testing market. The analysts of the report have performed in-depth primary and secondary research to analyze the key players and their market share. Further, different trusted sources were roped in to gather numbers, subdivisions, revenue and shares.

The research study encompasses fundamental points of the global Direct-To-Consumer (DTC) Genetic Testing market, from future prospects to the competitive scenario, extensively. The DROT and Porters Five Forces analyses provides a deep explanation of the factors affecting the growth of Direct-To-Consumer (DTC) Genetic Testing market. The Direct-To-Consumer (DTC) Genetic Testing market has been broken down into various segments, regions, end-uses and players to provide a clear picture of the present market situation to the readers. In addition, the macro- and microeconomic aspects are also included in the research.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2637644&source=atm

The key players covered in this studyAncestryColor GenomicsEasy DNAFamilytreeDNA (Gene By Gene)Full Genome CorporationHelix OpCo LLCIdentigeneKarmagenesLiving DNAMapmygenomeMyHeritagePathway GenomicsGenesis Healthcare23andMe

Market segment by Type, the product can be split intoCarrier TestingPredictive TestingAncestry & Relationship TestingNutrigenomics TestingOthersMarket segment by Application, split intoOnline PlatformsOver-the-Counter

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Direct-To-Consumer (DTC) Genetic Testing status, future forecast, growth opportunity, key market and key players.To present the Direct-To-Consumer (DTC) Genetic Testing development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Direct-To-Consumer (DTC) Genetic Testing are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Purchase reports at discounted prices!!! Offer valid till midnight!!!

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2637644&source=atm

The Direct-To-Consumer (DTC) Genetic Testing market research covers an exhaustive analysis of the following data:

The Direct-To-Consumer (DTC) Genetic Testing market research addresses critical questions, such as

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2637644&licType=S&source=atm

The global Direct-To-Consumer (DTC) Genetic Testing market research considers region 1 (Country 1, country 2), region 2 (Country 1, country 2) and region 3 (Country 1, country 2) as the important segments. All the recent trends, such as changing consumers demand, ecological conservation, and regulatory standards across different regions are covered in the report.

Read the rest here:
COVID-19: Responding to the business impacts of Good Growth Opportunities in Global Direct-To-Consumer (DTC) Genetic Testing Market - Cole of Duty

Safety4Her was founded by Melissa Gaglione, who saw a need and opportunity for womens clothing in the towing and trucking industry.

With the trucking, towing and manufacturing industry employing more than 5 million women and a growth rate of 22 percent annually, she decided it was time for clothing that women in those industries would want to wear.

I started my company, because I was a woman in the towing and trucking industry and found that wherever I searched, there was nothing that fit me, Gaglione said. There are no small sizes and everything was made in one size.

The existing market for safety wear is mostly for men and does not provide materials or fits that most women would find comfortable. A poor fit can cause women to face a higher risk of injury or death think baggy clothing caught in machinery which can also increase insurance risks.

In 2017 alone, Gaglione said, there were 250,000 accidents due to ill-fitting safety wear. Gaglione said she knows of some companies that sell pink safety wear, but much of it doesnt comply with the American National Standards Institute, which establishes various safety standards.

She not only made her clothing compliant with ANSI, but comfortable. All her garments are inspired by typical yoga pants, as she got her start by simply sewing on reflective gear to her yoga pants and leggings. She eventually made her own designs for women of all sizes.

Read the full story at WisBusiness.com: https://www.wisbusiness.com/?p=1452259

This weeks episode of WisBusiness: The Podcast features Buckley Brinkman, executive director and CEO of the Wisconsin Center for Manufacturing and Productivity.

WCMP collaborates with the UW Stout Manufacturing Outreach Center and the Wisconsin Manufacturing Extension Partnership to help the states manufacturers grow their businesses and become more profitable by offering services and programs.

What were doing now is helping manufacturers start to figure out how theyre going to operate, safely, responsibly and effectively as we come out of this as a state and as a nation, Buckley said.

Brinkman will also be a panelist at the 2020 Wisconsin Entrepreneurs Conference put on by the Wisconsin Technology Council on June 4. The virtual event will focus on COVID-19 economic survival, recovery and prosperity for young companies during a new normal.

He is bringing his broad perspective and connections with manufacturers across the nation, with knowledge on how cutting edge technology is implemented in manufacturing operations.

Every time we come out of a downturn, the investment in technology actually speeds up rather than slows down, said Brinkman. The companies that are going to come out of this stronger are the ones that are already making plans and looking for new opportunities for their businesses to take advantage of as the economy recovers.

Brinkman is looking forward to coming away with two or three ideas to put to use as well as two or three things that push him to think harder about what hes doing.

I just think this is an exciting time for us, I think its going to be an opportunity for all of us to show what Wisconsin can do, both in terms of our ability to open responsibility but then also to take advantage of the new opportunities that are coming along in this new economy, he said.

Listen to the podcast, sponsored by UW-Madison: https://www.wisbusiness.com/?p=1452256

The states unemployment rate soared to 14.1 percent in April, reaching a level not seen since the Great Depression.

According to a release from the state Department of Workforce Development, Wisconsins unemployment rate in April was 0.6 percent lower than the national rate of 14.7 percent.

The massive increase comes after the state was experiencing near-record low unemployment rates, with 3.1 percent in early March. More than 385,000 private-sector jobs were lost over the course of a single month, according to DWD.

The economy has taken a pretty severe hit in a very rapid manner, said DWD Chief Economist Dennis Winters in a media briefing today.

He explained the states unemployment rate approached 10 percent in the Great Recession of 2008, just under the national rate at the time. Winters also said the state didnt see current levels in a previous recession in the early 1980s.

The closest is the Great Depression when they figured the unemployment rate was around 25 percent, he said, adding that the depression of the 1930s built up over the course of months and years. This is a totally different phenomenon.

In early April, DWD had projected the states unemployment rate could reach as high as 27 percent. But based on the most recent information, Winters said the odds of that are less than 50 percent at this point.

Since the unemployment statistics are delayed by several weeks, Winters said they likely wont reflect the impact of the stay-at-home order and business restrictions being lifted until early July.

After peaking in early April, the number of initial unemployment applications in Wisconsin has since leveled off, according to the DWD website. But the daily totals are still in the thousands, and much higher than the same time last year. Between March 15 and May 16, DWD received 549,147 initial unemployment applications.

Wisconsin Manufacturers & Commerce President & CEO Kurt Bauer said a prolonged shutdown due to COVID-19 would likely be a much greater threat to the state than the virus itself.

Now is the time to return to the policies that delivered the strongest economy, lowest unemployment and largest budget reserves in Wisconsin history, he said. Wisconsin must reduce taxes, cut job-strangling red tape, and enact liability reforms that protect employers from costly and frivolous lawsuits.

See the release:

http://dwd.wisconsin.gov/news/2020/unemployment/200521-april-state.pdf

See the latest unemployment application numbers:

http://dwd.wisconsin.gov/covid19/public/ui-stats.htm

See the WMC statement:

Gov. Tony Evers says the state will dedicate $100 million from the federal CARES Act to help long-term care providers, emergency medical services, and home and community-based services.

The money is the latest chunk of the federal funding that Evers has rolled out to help various industries impacted by COVID-19. Hes now announced plans for more than $1.4 billion of the nearly $1.9 billion sent to the state.

The $100 million will be doled out in two parts. The initial phase will support immediate needs with a second release the administration says will be more targeted to additional needs of providers. In both cases, the money will support expenses directly related to COVID-19 and unexpected costs such as overtime and changes to sanitation procedures.

On a call with reporters today, Evers said the state will use how much Medicaid funding applicants receive as a basis to help divvy up the $100 million.

Evers acknowledged needs outstrip the amount of money being made available, noting he had earlier called for state money to help the facilities. But Republican lawmakers rejected his legislation that included the money.

Certainly, we will look at it, Evers said of additional state funding. But we also want to use as many resources as possible from the federal government.

Earlier today, Assembly Minority Leader Jim Steineke, R-Kaukauha, chided Evers in a letter for not providing money to long-term care facilities.

Following the announcement, Steineke said the money was better than nothing. Steineke added he heard frustrations from those in the long-term care industry that they hadnt been consulted by Evers and said providing state money isnt an option because Wisconsin is fundamentally broke.

While its a significant amount of money, in the long run its going to fall well short of what the needs are, Steineke said.

See the release:

Read Steinekes letter:

https://www.wispolitics.com/wp-content/uploads/2020/05/200521Steineke.pdf

A professor in the UW-Madison Department of Pathology and Laboratory Medicine, David OConnor, is working to develop a COVID-19 test to be used in institutions such as nursing homes or large workplaces.

OConnor was a panelist in the Wisconsin Alumni and Research Foundations third COVID-19 edition of its event series Crossroads of Ideas titled Where do we go from here?

He is anticipating federal guidelines are going to change on patients needing to be symptomatic for a test, as his lab is aiming for this test to be used for pre-symptomatic people.

He is working with Profs. Dave Beebe and Tom Friedrich to develop a colorimetric test for the virus, SARS-CoV-2 that causes the disease, COVID-19. OConnor said that one of the testing limitations right now is that it needs to take place in centralized labs with fancy equipment. But in this rapid test, a swab sample that has the viruss nucleic acid or RNA would cause the material in a tube to turn yellow; if not, pink.

We imagine that a truly rapid test would need to be deployed to nursing homes, said OConnor, noting that there are 15,000 nursing homes in the nation. You can imagine having a device that can be deployed at nursing homes, at any nursing home that has ongoing cases, it could be, having their people tested every day.

Deployment of the test would depend on a pending grant with RADx, a government program thats designed to accelerate the development and deployment of tests like this, according to OConnor.

If it gets funded, RADx will do rapid development over about a four-week period to see if it would be feasible for commercialization on a scale of millions of tests per week. If so, they aim to have it available by the end of the summer highly ambitious, especially from where we are now, he said.

Looking ahead, OConnor doesnt know how COVID-19 will behave in the winter.

A lot of people who believe they were infected last winter, were infected with something else, possibly influenza B, possibly something else, he said adding that probably only 1 percent of people in Dane County had it last winter, and they would have been classified at a higher than average risk level.

With most people having not been infected, certainly around here, its going to be an open question what happens next winter.

Also in OConnors Laboratory, investigators lead CoVen, an international collaboration developing COVID-19 animal models to test vaccines and treatments. The group has also been responsible for sequencing SARS-CoV-2 genomes from cases throughout Dane and Milwaukee Counties to understand how these viruses are moving through Wisconsin.

Gentueri Inc. contributes 55,000 COVID-19 testing kits a week to the states lab capacity and is developing new testing kits that can be used in the workplace.

Gentueris main business is working with laboratories to improve result quality and lab efficiency by advancing collection, preservation and processing of biological samples with kits. They make sexual assault kits for the Wisconsin Crime Lab, collection kits and genetic testing kits.

In mid-March, after predicting a slowdown in business, Nagy decided to expand Gentueri from four employees to 25 and pivoted to produce COVID-19 testing kits that include the nasal swabs and Viral Transport Media material that keeps the virus alive in the sample for the lab for local laboratories.

We realized that there was a shortage of the kits out there, and the fact that were a biological sample collection company we figured we have the expertise to make these, said Randy Nagy, president and CEO of Gentueri.

After a call to the state hygiene laboratory, company officials sourced the materials they would need for the kits, purchased a machine to make the kits and started producing the kits. Theyve since expanded to help other states in need: Illinois, Missouri, Indiana, Nebraska, Michigan and Kansas.

According to Nagy, what employers are looking for now is a way to test their employees to make them feel safe. With expertise in sample collection, Gentueri is developing a CollectEject Swab Kit that uses an oral sample rather than the long thin swab taken high up in the nasal cavity.

This allows an individual to easily collect a sample themselves and send it to a lab for automated processing, said Nagy.

We see a big opportunity there and that will go until there is a vaccine available, he said. This pivot has given us exposure to the genetic testing world. We can help the community and the laboratories with their immediate problem. Were not only doing it ourselves, but helping other companies in the end to provide their services as well.

DHS is conducting 376 facility-wide investigations across the state, 77 more than last week.

Long-term care facilities account for 165 of them, followed closely by 148 non-health care workplace investigations.

Long-term care facilities in the state are reporting 205 deaths due to COVID-19, making up 42 percent of total deaths in Wisconsin due to the virus.

These include nursing homes and assisted living facilities, such as community-based residential facilities and residential care apartment complexes.

Thirty-two of the investigations are in group housing facilities including correctional facilities, homeless shelters, dormitories and group homes that have identified 21 COVID-19 deaths, or 4 percent of the states total.

One hundred and twenty-nine of the states COVID-19 deaths were not linked to group housing facilities, but 132 deaths are categorized as unknown, meaning they may or may not have occurred at these facilities.

According to DHS, the unknown category exists because relevant information has only been collected since April 8.

About 18 percent of confirmed COVID-19 patients who have died in the state were over 90 years old, while another 24 percent were between 80 and 89 years old. Another 28 percent were between 70 and 79, and 16 percent were between 60 and 69.

DHS is also conducting investigations in healthcare facilities (17) and other settings (14).

A majority of the investigations are taking place in Milwaukee (69) and Brown (60) counties.

Click here to see the facilities under investigation and a breakdown by county: https://www.dhs.wisconsin.gov/covid-19/investigations.htm

All 72 counties in Wisconsin have at least one confirmed case of COVID-19 after Langlade and Taylor counties had a case overnight.

DHS reports the states COVID-19 death toll at 487 up six from the last count.

The states number of confirmed cases also rose since the previous count by 472 bringing the cumulative case count to 13,885. The positive tests results account for 5 percent of the total tests received Thursday, which is a good percentage, DHS Secretary Andrea Palm said in a briefing.

An estimated 58 percent have recovered from COVID-19, while 4 percent of patients have died. Thirty-nine percent are still in a 30-day waiting period of symptom onset or diagnosis.

Counties reporting deaths include: Milwaukee (269), Brown (29), Dane (26), Waukesha (24), Kenosha (21), Racine (20), Rock (14), Ozaukee (11), Walworth (11), Grant (10), Outagamie (5), Clark (4), Fond du Lac (4), Richland (4) and Washington (4).

Door, Richland, Sauk and Sheboygan counties report three deaths each. Jefferson and Marinette counties report two deaths each.

Adams, Bayfield, Buffalo, Burnett, Calumet, Columbia, Dodge, Iron, Jackson, Juneau, Kewaunee, Manitowoc, Marathon, Marquette, Monroe, Polk, Waupaca and Winnebago counties report one death each.

Hospitalizations in the state are up.

Of the states 13,885 confirmed cases, 16 percent have been hospitalized and 4 percent have received intensive care, according to DHS.

And the Wisconsin Hospital Associations hospital dashboard reports 398 COVID patients in hospitals statewide, up five patients from Wednesday and 46 more than a week ago. WHAs statewide patient data shows an upward trend in hospitalized patients since May 6.

DHS Secretary Andrea Palm said its safe to say the uptick in hospitalizations right now is not a result of the end of the states stay-at-home order.

This is because hospitalization lag time is longer than the testing lag time and hospitalization isnt required until a patient has been infected for a while and symptoms get bad, usually three to five weeks post infection, according to Palm.

DHS reports that 292 of the total COVID patients are in southeastern Wisconsin, which has also seen an increase in hospitalizations since May 6.

It is why we have built and worked on this surge capacity, not only at the regional level with hospital systems across the state, but also through our alternative care facility in Milwaukee and the one that we have started here in Dane that we would be able stand up quickly if we needed to, Palm said.

The state is slowly moving up to reach its capacity of 14,140 tests per day after a total of 9,365 came back Thursday, the most of any day.

If youre experiencing any symptoms of COVID-19, please get a test, Palm said.

Click here for more coronavirus resources and updates: https://www.wispolitics.com/wisconsin-coronavirus-resources/

As White House officials reportedly pressure the CDC to raise the bar for how states count COVID-19 deaths, the state Department of Health Services says its only including cases that had a positive test and for which the virus caused the patient to die.

If they tested positive for COVID-19 by a confirmatory test (for example, a PCR test that detects the virus causing COVID-19, not an antibody test), and COVID-19 is listed among the primary causes of death or among contributing causes of death, they are counted as a COVID-19-associated death, said Elizabeth Goodsitt, a spokesperson for DHS.

According to a report from the Daily Beast, members of the presidents coronavirus task force have been seeking changes to the tallying process that would likely lead to fewer deaths being reported. The report cites five unnamed CDC officials and says President Trump has used hypotheticals in which someone who has the virus dies from an unrelated cause such as falling down the stairs, and is still counted as a COVID-19 death.

Other states are using varying methods to calculate the total death toll attributed to the virus, a report from the Washington Post shows. But in Wisconsin, health officials only count it as a COVID-19 death if the disease is listed among the primary causes of death or contributing causes of death.

Goodsitt said if health officials have reason to believe a death wasnt linked to COVID-19 at all, based on the assessment of a medical provider or medical examiner, then its not counted in the states tally of virus deaths.

For example, if a patient died from an overdose or a car accident, and they were not ill, or there was evidence that their illness did not contribute to their death, they are not counted as a COVID-19-associated death, even if COVID-19 is detected, Goodsitt said in an email.

See more in Top Stories below.

#TOP STORIES#

# Medical College CEO: Wisconsin has landmark day in testing Covid-19

Originally posted here:
FRI AM News: Safety4Her aims to provide the right clothing for women in the trades; WisBusiness: The Podcast features Buckley Brinkman, WCMP -...

(WZAW) -- The current pandemic has upended so many aspects of everyday life, but for people considering pregnancy or already pregnant, those changes can feel even more overwhelming. With medical appointments delayed or moved to telemedicine sessions, many women may feel more uncertainty about their healthcare.

On Wednesday, genetic counselor and womens health expert Julia Wilkinson joined NewsChannel 7 at 4 to share specific steps you and your partner can do during this time while youre at home to make sure youre ready for your next appointment, either via telemedicine or in person.

The first thing Wilkinson talked about was the importance of doing your research. Gather information from both your and your partners relatives to learn about your familys health history.

Find out if theres anything in that history that you might be concerned about for your own health or for the health of your future children, she said.

Also, she said to track your menstrual cycles if youre not already doing so. Also consider taking an ovulation test or fertility test if theyve been irregular.

Wilkinson said you should also be gathering your medical records into one location, especially if youre been seeing different physicians in the last five years. Contact their offices to obtain your medical records. If not, make a list of any health events or significant medical activities. Its also a good way to be sure youre up to date on vaccines.

Lastly Wilkinson said that genetic testing is incredibly important for everyone to have. Parents may have genetic conditions that can be passed onto unborn children. Leading health organizations recommend carrier screening be offered to all women who are pregnant or planning on becoming pregnant. Tests kits are available online and can be done right at home.

That way you can do everything you need to do to prepare for that next appointment, she added.

For more information visit http://www.invitae.com

Go here to read the rest:
Family planning during the COVID-19 pandemic - WSAW

Imagine if one company held a patent covering all methods of testing for Covid-19 antibodies. The company could charge monopoly prices for its tests and prohibit competitors including non-profit and university labs from manufacturing or administering their own. If the company made itself the countrys sole supplier, it would struggle to meet demand. The company would profit, but Americans would face waiting lists, confusion and inequitable access and the virus would keep spreading.

Would a patent holder ever exploit an outbreak of life-threatening infectious disease in this way? Yes. In 2001, the United States faced a credible threat of an anthrax outbreak, yet Bayer refused to license its patents on ciprofloxacin (Cipro), the most effective antibiotic treatment for anthrax, to competitors, even as Bayer itself struggled to supply the nations antibiotic stockpile.

It may seem outlandish to imagine one patent creating a wide-ranging monopoly on diagnostic testing, but it happened. In the 1990s and 2000s, biotech companies obtained and enforced broad patents on medical diagnostics that gave them near-total control of testing for particular conditions. One company obtained patents on methods of diagnosing people at high risk of developing breast cancer and attempted to eliminate testing at competing laboratories by sending cease-and-desist letters; another became the sole provider of genetic testing for many neurological and endocrine conditions, including muscular dystrophy and Alzheimers disease.

By 2011, the American Medical Association submitted an alarmed amicus brief to the US supreme court, lamenting that [i]t is hard to imagine how the clinical diagnostic community will continue to provide quality patient care and how physicians will continue to practice medicine in an ethical and effective manner under a patent regime that permits broad patents on the bodys natural responses to illness and medical treatment.

The supreme court listened. Between 2012 and 2014, in a trio of important cases Mayo, Myriad and Alice it confirmed that if a patent is directed to an abstract idea, natural phenomenon or natural law, it must claim something new and attributable to the inventor an inventive concept to become eligible for patent protection. A patent cant broadly claim a fundamental building block of knowledge like the human bodys antibodies to Covid-19 and tack on ubiquitous, conventional technology like using a needle to draw a blood sample containing those antibodies. These supreme court decisions helped restore patent laws traditional balance between inventors incentives and public access to technology.

The United Statess innovation economy has grown under Mayo, Myriad and Alice, with benefits to healthcare and not just diagnostic testing. For example, in 2013, Justus Decher developed a telehealth product that enables patients to consult with doctors remotely. A few years later, Decher was accused of infringing an older patent so broad it covered the basic idea of remotely consulting patients even by telephone. Fortunately, a court invalidated the patent under the supreme courts Mayo and Alice precedents. Dechers and other telehealth technologies have provided an important lifeline in the Covid-19 pandemic.

Pro-patent voices are now using the Covid-19 crisis to push the Coons-Tillis bill

Freed from overbroad patents on fundamental knowledge, we see an explosion of efforts to build and disseminate new tools to fight Covid-19, including 3-D printed and open source masks and ventilators and clinical trials on dozens of potential treatments and vaccines. While the US lags on deploying diagnostic testing, inventors are busily inventing: the FDA has authorized dozens of different Covid-19 tests. Some inventors may be motivated by the patent incentive companies can still get patents, just within limits. But much is driven by altruism, love of science and the reputation that comes from inventing something that saves millions of lives. Today, no one company monopolizes Covid-19 testing, and all benefit.

Yet some patent holders and their allies are unwisely threatening this balance. Last year, with support from the largest pharmaceutical and biotech industry trade groups, Senators Chris Coons and Thom Tillis proposed a bill that would undo Mayo, Myriad, and Alice, expanding limits on patent eligibility. Pro-patent voices are now using the Covid-19 crisis to push the Coons-Tillis bill, asserting that broad patents on now-patent-ineligible subject matter are necessary to incentivize invention of anti-Covid technologies, especially diagnostic tests. That ignores evidence that the biggest problems we face are global shortages of unpatented basic supplies like nasal swabs and a failure of federal government coordination, not a shortage of inventive activity.

Congress should reject these efforts to undo the traditional balance and expand the scope of patent eligibility. The current legal standard may not be perfect, but it is working. In the Covid-19 crisis, Congress should focus instead on policies that give healthcare workers, other essential workers, patients, and all Americans the resources they need.

Chris Morten is the supervising attorney at NYU Laws Technology Law & Policy Clinic and a fellow at NYU and Yale Law Schools. Alex Moss is a staff attorney at the Electronic Frontier Foundation, specializing in intellectual property

Follow this link:
Could a patent get in between you and a Covid-19 test? Yes - The Guardian

Los Angeles, United StatesThe report offers an all-inclusive and accurate research study on the global Direct-Access Genetic Testing market while chiefly focusing on current and historical market scenarios. Stakeholders, market players, investors, and other market participants can significantly benefit from the thorough market analysis provided in the report. The authors of the report have compiled a detailed study on crucial market dynamics, including growth drivers, restraints, and opportunities. This study will help market participants to get a good understanding of future development of the global Direct-Access Genetic Testing market. The report also focuses on market taxonomy, regional analysis, opportunity assessment, and vendor analysis to help with comprehensive evaluation of the global Direct-Access Genetic Testing market.

Key companies operating in the global Direct-Access Genetic Testing market include : , 23andMe, MyHeritage, LabCorp, Myriad Genetics, Ancestry.com, Quest Diagnostics, Gene By Gene, DNA Diagnostics Center, Invitae, IntelliGenetics, Ambry Genetics, Living DNA, EasyDNA, Pathway Genomics, Centrillion Technology, Xcode, Color Genomics, Anglia DNA Services, African Ancestry, Canadian DNA Services, DNA Family Check, Alpha Biolaboratories, Test Me DNA, 23 Mofang, Genetic Health, DNA Services of America, Shuwen Health Sciences, Mapmygenome, Full Genomes Direct-Access Genetic Testing

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1698253/covid-19-impact-on-global-direct-access-genetic-testing-market

Segment Analysis

The segmental analysis will help companies to focus on high-growth areas of the global Direct-Access Genetic Testing market. In order to broaden the overall understanding of the global Direct-Access Genetic Testing industry, the report has segregated the global Direct-Access Genetic Testing business into varied segments comprising product type, application, and end user. This examination has been carried out based on parameters like size, CAGR, share, production, and consumption. Also, region-wise assessment, wherein lucrative prospects that a region or country is likely to offer has been explored.

Global Direct-Access Genetic Testing Market Segment By Type:

, Diagnostic Screening, PGD, Relationship testing Direct-Access Genetic Testing

Global Direct-Access Genetic Testing Market Segment By Application:

, Diagnostic Screening, PGD, Relationship testing Direct-Access Genetic Testing

Competitive Landscape:

It is important for every market participant to be familiar with the competitive scenario in the global Direct-Access Genetic Testing industry. In order to fulfill the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Direct-Access Genetic Testing market include : , 23andMe, MyHeritage, LabCorp, Myriad Genetics, Ancestry.com, Quest Diagnostics, Gene By Gene, DNA Diagnostics Center, Invitae, IntelliGenetics, Ambry Genetics, Living DNA, EasyDNA, Pathway Genomics, Centrillion Technology, Xcode, Color Genomics, Anglia DNA Services, African Ancestry, Canadian DNA Services, DNA Family Check, Alpha Biolaboratories, Test Me DNA, 23 Mofang, Genetic Health, DNA Services of America, Shuwen Health Sciences, Mapmygenome, Full Genomes Direct-Access Genetic Testing

Key Questions Answered

Enquire for Customization in this Report: https://www.qyresearch.com/customize-request/form/1698253/covid-19-impact-on-global-direct-access-genetic-testing-market

Table of Contents

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Direct-Access Genetic Testing Revenue1.4 Market Analysis by Type1.4.1 Global Direct-Access Genetic Testing Market Size Growth Rate by Type: 2020 VS 20261.4.2 Diagnostic Screening1.4.3 PGD1.4.4 Relationship testing1.5 Market by Application1.5.1 Global Direct-Access Genetic Testing Market Share by Application: 2020 VS 20261.5.2 Online1.5.3 Offline1.6 Coronavirus Disease 2019 (Covid-19): Direct-Access Genetic Testing Industry Impact1.6.1 How the Covid-19 is Affecting the Direct-Access Genetic Testing Industry

1.6.1.1 Direct-Access Genetic Testing Business Impact Assessment Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and Direct-Access Genetic Testing Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for Direct-Access Genetic Testing Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered 2 Global Growth Trends by Regions2.1 Direct-Access Genetic Testing Market Perspective (2015-2026)2.2 Direct-Access Genetic Testing Growth Trends by Regions2.2.1 Direct-Access Genetic Testing Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Direct-Access Genetic Testing Historic Market Share by Regions (2015-2020)2.2.3 Direct-Access Genetic Testing Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Direct-Access Genetic Testing Market Growth Strategy2.3.6 Primary Interviews with Key Direct-Access Genetic Testing Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Direct-Access Genetic Testing Players by Market Size3.1.1 Global Top Direct-Access Genetic Testing Players by Revenue (2015-2020)3.1.2 Global Direct-Access Genetic Testing Revenue Market Share by Players (2015-2020)3.1.3 Global Direct-Access Genetic Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Direct-Access Genetic Testing Market Concentration Ratio3.2.1 Global Direct-Access Genetic Testing Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Direct-Access Genetic Testing Revenue in 20193.3 Direct-Access Genetic Testing Key Players Head office and Area Served3.4 Key Players Direct-Access Genetic Testing Product Solution and Service3.5 Date of Enter into Direct-Access Genetic Testing Market3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Direct-Access Genetic Testing Historic Market Size by Type (2015-2020)4.2 Global Direct-Access Genetic Testing Forecasted Market Size by Type (2021-2026) 5 Direct-Access Genetic Testing Breakdown Data by Application (2015-2026)5.1 Global Direct-Access Genetic Testing Market Size by Application (2015-2020)5.2 Global Direct-Access Genetic Testing Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Direct-Access Genetic Testing Market Size (2015-2020)6.2 Direct-Access Genetic Testing Key Players in North America (2019-2020)6.3 North America Direct-Access Genetic Testing Market Size by Type (2015-2020)6.4 North America Direct-Access Genetic Testing Market Size by Application (2015-2020) 7 Europe7.1 Europe Direct-Access Genetic Testing Market Size (2015-2020)7.2 Direct-Access Genetic Testing Key Players in Europe (2019-2020)7.3 Europe Direct-Access Genetic Testing Market Size by Type (2015-2020)7.4 Europe Direct-Access Genetic Testing Market Size by Application (2015-2020) 8 China8.1 China Direct-Access Genetic Testing Market Size (2015-2020)8.2 Direct-Access Genetic Testing Key Players in China (2019-2020)8.3 China Direct-Access Genetic Testing Market Size by Type (2015-2020)8.4 China Direct-Access Genetic Testing Market Size by Application (2015-2020) 9 Japan9.1 Japan Direct-Access Genetic Testing Market Size (2015-2020)9.2 Direct-Access Genetic Testing Key Players in Japan (2019-2020)9.3 Japan Direct-Access Genetic Testing Market Size by Type (2015-2020)9.4 Japan Direct-Access Genetic Testing Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Direct-Access Genetic Testing Market Size (2015-2020)10.2 Direct-Access Genetic Testing Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Direct-Access Genetic Testing Market Size by Type (2015-2020)10.4 Southeast Asia Direct-Access Genetic Testing Market Size by Application (2015-2020) 11 India11.1 India Direct-Access Genetic Testing Market Size (2015-2020)11.2 Direct-Access Genetic Testing Key Players in India (2019-2020)11.3 India Direct-Access Genetic Testing Market Size by Type (2015-2020)11.4 India Direct-Access Genetic Testing Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Direct-Access Genetic Testing Market Size (2015-2020)12.2 Direct-Access Genetic Testing Key Players in Central & South America (2019-2020)12.3 Central & South America Direct-Access Genetic Testing Market Size by Type (2015-2020)12.4 Central & South America Direct-Access Genetic Testing Market Size by Application (2015-2020) 13 Key Players Profiles13.1 23andMe13.1.1 23andMe Company Details13.1.2 23andMe Business Overview and Its Total Revenue13.1.3 23andMe Direct-Access Genetic Testing Introduction13.1.4 23andMe Revenue in Direct-Access Genetic Testing Business (2015-2020))13.1.5 23andMe Recent Development13.2 MyHeritage13.2.1 MyHeritage Company Details13.2.2 MyHeritage Business Overview and Its Total Revenue13.2.3 MyHeritage Direct-Access Genetic Testing Introduction13.2.4 MyHeritage Revenue in Direct-Access Genetic Testing Business (2015-2020)13.2.5 MyHeritage Recent Development13.3 LabCorp13.3.1 LabCorp Company Details13.3.2 LabCorp Business Overview and Its Total Revenue13.3.3 LabCorp Direct-Access Genetic Testing Introduction13.3.4 LabCorp Revenue in Direct-Access Genetic Testing Business (2015-2020)13.3.5 LabCorp Recent Development13.4 Myriad Genetics13.4.1 Myriad Genetics Company Details13.4.2 Myriad Genetics Business Overview and Its Total Revenue13.4.3 Myriad Genetics Direct-Access Genetic Testing Introduction13.4.4 Myriad Genetics Revenue in Direct-Access Genetic Testing Business (2015-2020)13.4.5 Myriad Genetics Recent Development13.5 Ancestry.com13.5.1 Ancestry.com Company Details13.5.2 Ancestry.com Business Overview and Its Total Revenue13.5.3 Ancestry.com Direct-Access Genetic Testing Introduction13.5.4 Ancestry.com Revenue in Direct-Access Genetic Testing Business (2015-2020)13.5.5 Ancestry.com Recent Development13.6 Quest Diagnostics13.6.1 Quest Diagnostics Company Details13.6.2 Quest Diagnostics Business Overview and Its Total Revenue13.6.3 Quest Diagnostics Direct-Access Genetic Testing Introduction13.6.4 Quest Diagnostics Revenue in Direct-Access Genetic Testing Business (2015-2020)13.6.5 Quest Diagnostics Recent Development13.7 Gene By Gene13.7.1 Gene By Gene Company Details13.7.2 Gene By Gene Business Overview and Its Total Revenue13.7.3 Gene By Gene Direct-Access Genetic Testing Introduction13.7.4 Gene By Gene Revenue in Direct-Access Genetic Testing Business (2015-2020)13.7.5 Gene By Gene Recent Development13.8 DNA Diagnostics Center13.8.1 DNA Diagnostics Center Company Details13.8.2 DNA Diagnostics Center Business Overview and Its Total Revenue13.8.3 DNA Diagnostics Center Direct-Access Genetic Testing Introduction13.8.4 DNA Diagnostics Center Revenue in Direct-Access Genetic Testing Business (2015-2020)13.8.5 DNA Diagnostics Center Recent Development13.9 Invitae13.9.1 Invitae Company Details13.9.2 Invitae Business Overview and Its Total Revenue13.9.3 Invitae Direct-Access Genetic Testing Introduction13.9.4 Invitae Revenue in Direct-Access Genetic Testing Business (2015-2020)13.9.5 Invitae Recent Development13.10 IntelliGenetics13.10.1 IntelliGenetics Company Details13.10.2 IntelliGenetics Business Overview and Its Total Revenue13.10.3 IntelliGenetics Direct-Access Genetic Testing Introduction13.10.4 IntelliGenetics Revenue in Direct-Access Genetic Testing Business (2015-2020)13.10.5 IntelliGenetics Recent Development13.11 Ambry Genetics10.11.1 Ambry Genetics Company Details10.11.2 Ambry Genetics Business Overview and Its Total Revenue10.11.3 Ambry Genetics Direct-Access Genetic Testing Introduction10.11.4 Ambry Genetics Revenue in Direct-Access Genetic Testing Business (2015-2020)10.11.5 Ambry Genetics Recent Development13.12 Living DNA10.12.1 Living DNA Company Details10.12.2 Living DNA Business Overview and Its Total Revenue10.12.3 Living DNA Direct-Access Genetic Testing Introduction10.12.4 Living DNA Revenue in Direct-Access Genetic Testing Business (2015-2020)10.12.5 Living DNA Recent Development13.13 EasyDNA10.13.1 EasyDNA Company Details10.13.2 EasyDNA Business Overview and Its Total Revenue10.13.3 EasyDNA Direct-Access Genetic Testing Introduction10.13.4 EasyDNA Revenue in Direct-Access Genetic Testing Business (2015-2020)10.13.5 EasyDNA Recent Development13.14 Pathway Genomics10.14.1 Pathway Genomics Company Details10.14.2 Pathway Genomics Business Overview and Its Total Revenue10.14.3 Pathway Genomics Direct-Access Genetic Testing Introduction10.14.4 Pathway Genomics Revenue in Direct-Access Genetic Testing Business (2015-2020)10.14.5 Pathway Genomics Recent Development13.15 Centrillion Technology10.15.1 Centrillion Technology Company Details10.15.2 Centrillion Technology Business Overview and Its Total Revenue10.15.3 Centrillion Technology Direct-Access Genetic Testing Introduction10.15.4 Centrillion Technology Revenue in Direct-Access Genetic Testing Business (2015-2020)10.15.5 Centrillion Technology Recent Development13.16 Xcode10.16.1 Xcode Company Details10.16.2 Xcode Business Overview and Its Total Revenue10.16.3 Xcode Direct-Access Genetic Testing Introduction10.16.4 Xcode Revenue in Direct-Access Genetic Testing Business (2015-2020)10.16.5 Xcode Recent Development13.17 Color Genomics10.17.1 Color Genomics Company Details10.17.2 Color Genomics Business Overview and Its Total Revenue10.17.3 Color Genomics Direct-Access Genetic Testing Introduction10.17.4 Color Genomics Revenue in Direct-Access Genetic Testing Business (2015-2020)10.17.5 Color Genomics Recent Development13.18 Anglia DNA Services10.18.1 Anglia DNA Services Company Details10.18.2 Anglia DNA Services Business Overview and Its Total Revenue10.18.3 Anglia DNA Services Direct-Access Genetic Testing Introduction10.18.4 Anglia DNA Services Revenue in Direct-Access Genetic Testing Business (2015-2020)10.18.5 Anglia DNA Services Recent Development13.19 African Ancestry10.19.1 African Ancestry Company Details10.19.2 African Ancestry Business Overview and Its Total Revenue10.19.3 African Ancestry Direct-Access Genetic Testing Introduction10.19.4 African Ancestry Revenue in Direct-Access Genetic Testing Business (2015-2020)10.19.5 African Ancestry Recent Development13.20 Canadian DNA Services10.20.1 Canadian DNA Services Company Details10.20.2 Canadian DNA Services Business Overview and Its Total Revenue10.20.3 Canadian DNA Services Direct-Access Genetic Testing Introduction10.20.4 Canadian DNA Services Revenue in Direct-Access Genetic Testing Business (2015-2020)10.20.5 Canadian DNA Services Recent Development13.21 DNA Family Check10.21.1 DNA Family Check Company Details10.21.2 DNA Family Check Business Overview and Its Total Revenue10.21.3 DNA Family Check Direct-Access Genetic Testing Introduction10.21.4 DNA Family Check Revenue in Direct-Access Genetic Testing Business (2015-2020)10.21.5 DNA Family Check Recent Development13.22 Alpha Biolaboratories10.22.1 Alpha Biolaboratories Company Details10.22.2 Alpha Biolaboratories Business Overview and Its Total Revenue10.22.3 Alpha Biolaboratories Direct-Access Genetic Testing Introduction10.22.4 Alpha Biolaboratories Revenue in Direct-Access Genetic Testing Business (2015-2020)10.22.5 Alpha Biolaboratories Recent Development13.23 Test Me DNA10.23.1 Test Me DNA Company Details10.23.2 Test Me DNA Business Overview and Its Total Revenue10.23.3 Test Me DNA Direct-Access Genetic Testing Introduction10.23.4 Test Me DNA Revenue in Direct-Access Genetic Testing Business (2015-2020)10.23.5 Test Me DNA Recent Development13.24 23 Mofang10.24.1 23 Mofang Company Details10.24.2 23 Mofang Business Overview and Its Total Revenue10.24.3 23 Mofang Direct-Access Genetic Testing Introduction10.24.4 23 Mofang Revenue in Direct-Access Genetic Testing Business (2015-2020)10.24.5 23 Mofang Recent Development13.25 Genetic Health10.25.1 Genetic Health Company Details10.25.2 Genetic Health Business Overview and Its Total Revenue10.25.3 Genetic Health Direct-Access Genetic Testing Introduction10.25.4 Genetic Health Revenue in Direct-Access Genetic Testing Business (2015-2020)10.25.5 Genetic Health Recent Development13.26 DNA Services of America10.26.1 DNA Services of America Company Details10.26.2 DNA Services of America Business Overview and Its Total Revenue10.26.3 DNA Services of America Direct-Access Genetic Testing Introduction10.26.4 DNA Services of America Revenue in Direct-Access Genetic Testing Business (2015-2020)10.26.5 DNA Services of America Recent Development13.27 Shuwen Health Sciences10.27.1 Shuwen Health Sciences Company Details10.27.2 Shuwen Health Sciences Business Overview and Its Total Revenue10.27.3 Shuwen Health Sciences Direct-Access Genetic Testing Introduction10.27.4 Shuwen Health Sciences Revenue in Direct-Access Genetic Testing Business (2015-2020)10.27.5 Shuwen Health Sciences Recent Development13.28 Mapmygenome10.28.1 Mapmygenome Company Details10.28.2 Mapmygenome Business Overview and Its Total Revenue10.28.3 Mapmygenome Direct-Access Genetic Testing Introduction10.28.4 Mapmygenome Revenue in Direct-Access Genetic Testing Business (2015-2020)10.28.5 Mapmygenome Recent Development13.29 Full Genomes10.29.1 Full Genomes Company Details10.29.2 Full Genomes Business Overview and Its Total Revenue10.29.3 Full Genomes Direct-Access Genetic Testing Introduction10.29.4 Full Genomes Revenue in Direct-Access Genetic Testing Business (2015-2020)10.29.5 Full Genomes Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.

Excerpt from:
Direct-Access Genetic Testing Market which company is the market leader and how much its sales in 2020 and what it's expected sales for the next 5...

A leading research firmZion Market researchadded a recent report on Direct-to-Consumer (DTC) Genetic Testing Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20182026 to its research database. The Direct-to-Consumer (DTC) Genetic Testing comprehensive is perceptible among the most immensely gathered market globally. The Direct-to-Consumer (DTC) Genetic Testing report gives the exchange information and the progressing business chain information in the overall market. The report gives a thought with respect to the advancement of the free market movement of significant players of theDirect-to-Consumer (DTC) Genetic Testing. A noteworthy examination of the market relies upon general plans, which have been of late organized to the investigation of Direct-to-Consumer (DTC) Genetic Testing, is furthermore incorporated into the report.

FREE | Request Sample is Available @https://www.zionmarketresearch.com/sample/direct-to-consumer-genetic-testing-market

Some of the MajorDirect-to-Consumer (DTC) Genetic TestingPlayers Are:

23andMe, Ancestry, Color, EasyDNA, Family Tree DNA, Full Genomes, Genesis HealthCare, Helix, Identigene, Karmagenes, Living DNA

The Direct-to-Consumer (DTC) Genetic Testing report thinks about the present execution of the overall market notwithstanding the novel examples and furthermore a complete bifurcation product, its end-users, applications, and others of the market; additionally, the factual studying report does predictions on the accompanying power of the market reliant on this examination. The Direct-to-Consumer (DTC) Genetic Testing measurable looking over examination incorporates all parts of the overall market, which starts from perception the Direct-to-Consumer (DTC) Genetic Testing, collaborating with customers, and assessing the data of the overall market. Each division of the overall market is researched and isolated dependent on the sort of stock, their applications, and the end-customers.

The worldwide geological [Latin America, North America, Asia Pacific, Middle & East Africa, and Europe] analysis of the Direct-to-Consumer (DTC) Genetic Testing plan has furthermore been done cautiously in this report. The dynamic establishment of the overall Direct-to-Consumer (DTC) Genetic Testing depends on the assessment of item circulated in various markets, limitations, general benefits made by every association, and future aspirations. The major application areas of Direct-to-Consumer (DTC) Genetic Testing are also covered on the basis of their implementation. The report gives the ideology about different factors and inclinations affecting the development course of the worldwide Direct-to-Consumer (DTC) Genetic Testing. A review of the impact of the administrative regulations and policies on the Direct-to-Consumer (DTC) Genetic Testing operations is also included in this report. The Direct-to-Consumer (DTC) Genetic Testing report offers a complete analysis of competitive dynamics that are modifying and places the patrons ahead of competitors.

Download Free PDF Report Brochure @https://www.zionmarketresearch.com/requestbrochure/direct-to-consumer-genetic-testing-market

Promising Regions & Countries Mentioned In TheDirect-to-Consumer (DTC) Genetic TestingReport:

What ourDirect-to-Consumer (DTC) Genetic Testingreport offers:

Inquire more about this report @https://www.zionmarketresearch.com/inquiry/direct-to-consumer-genetic-testing-market

Key Topics Covered:

1. Introduction

2. Executive Summarya

3. Direct-to-Consumer (DTC) Genetic Testing Market Dynamics

4. Global Direct-to-Consumer (DTC) Genetic Testing Competitive Landscape

5. Global Direct-to-Consumer (DTC) Genetic Testing Therapy Type Segment Analysis

6. Global Direct-to-Consumer (DTC) Genetic Testing Therapeutic Area Segment Analysis

7. Global Direct-to-Consumer (DTC) Genetic Testing End-User Segment Analysis

8. Global Direct-to-Consumer (DTC) Genetic Testing Regional Segment Analysis

Request Report TOC (Table of Contents) @https://www.zionmarketresearch.com/toc/direct-to-consumer-genetic-testing-market

Reason to Buy

Also, Research Report Examines:

Thanks for reading this article;you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Us:

Zion Market Researchis an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the clients needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to usafter allif you do well, a little of the light shines on us.

Contact Us:

Zion Market Research244 Fifth Avenue, Suite N202New York, 10001, United StatesTel: +49-322 210 92714USA/Canada Toll Free No.1-855-465-4651

Email:[emailprotected]

Web:https://www.zionmarketresearch.com

Read the original post:
Global Direct-to-Consumer (DTC) Genetic Testing Market with (Covid-19) Impact Analysis: Latest Industry Trends and Insights, 2020-2027 - 3rd Watch...

The report on preimplantation genetic testing market provides a complete assessment of this industry vertical, along with an exhaustive analysis of various market segmentations. The report includes an in-depth, extensive study of this market in tandem with vital parameters that are likely to have an effect on the market commercialization matrix.

Top Companies:

Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., CooperSurgical, Inc., Beijing Genomics Institute (BGI), Abbott Laboratories, Natera, Inc., Genea Limited, Rubicon Genomics, Inc. and Oxford Gene Technology

Request sample copy of this report at: https://www.adroitmarketresearch.com/contacts/request-sample/1483

The preimplantation genetic testing Market report also provides the market impact and new opportunities created due to the COVID19/CORONA Virus Catastrophe. The total market is further divided by company, by country, and by application/types for the competitive landscape analysis. The report then estimates 2020-2025 market development trends of preimplantation genetic testing Industry.

The preimplantation genetic testing market report consists of information related to the projected CAGR of the global industry over the forecast period. Also, the numerous technological developments and innovations that are likely to drive the global preimplantation genetic testing market share over the anticipated period are mentioned in the study.

The report covers forecast and analysis for the preimplantation genetic testing market on a global and regional level. The study provides historic data of 2016 to 2019, considering 2019 as the base year, along with a forecast from 2020 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the preimplantation genetic testing market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the preimplantation genetic testing market on a global level.

Click here for detailed table of contents: https://www.adroitmarketresearch.com/industry-reports/preimplantation-genetic-testing-market

Global preimplantation genetic testing market is segmented based by type, application and region.

Based on Type, the market has been segmented into:

by Test Type (Aneuploidy, Structural Chromosomal Abnormalities, Single Gene Disorders, X-linked Disorders, HLA Typing, Gender Identification) and Technology (Next Generation Sequencing, Polymerase Chain Reaction, Fluorescent In-Situ Hybridization, Comparative Genomic Hybridization, Single Nucleotide Polymorphism)

In order to give the users of this report a comprehensive view, we have included various industry analysis models in our report and extensively demonstrated the key business strategies and competitive landscape of the preimplantation genetic testing market in our study. Our study also includes an analysis of Porters Five Forces framework for understanding the competitive strategies adopted by various stakeholders involved in the entire value chain of the preimplantation genetic testing market.

Key insights from the preimplantation genetic testing market report: Detailed summary of the regional terrain of the preimplantation genetic testing market. The study offers a succinct overview of the regional topography of the market, while categorizing the same into United States, China, Europe, Japan, and Southeast Asia & India. The report presents data pertaining to market share held by each region, alongside the growth potentials of various geographies. Growth rate attained by each region over the forecast period is depicted in the report.

Do you have any query or specific requirement? Ask to our industry expert at: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/1483

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Follow this link:
Preimplantation Genetic Testing Market 2019 Industry Outline, Global Executive Players, Interpretation and Benefit Growth to 2025 - Cole of Duty

Editors note: A version of this summary was provided by getAbstract.

The internet sparked rapid standardization within value chains, enabling innovative interlopers to break them faster than ever before. Yet, companies that occupy only a small space in an ecosystem risk losing sight of the big picture. Often, these disrupters focus solely on consumer demand without regard for any long-term negative consequences on society. SAP chief innovation officer Max Wessel explains why its in your businesss best interest to develop technology that addresses potential ethical issues from the very start.

The creators of autonomous automobiles carefully considered the moral issues pertaining to the development of technology that enables multiton vehicles to operate in the same space as pedestrians and human-driven transportation, Wessel notes. However, not all technology innovators tread as carefully. Often, disrupters limit their visions to fulfilling consumer demands with cheaper, less complicated, and more accessible products without considering the long-term repercussions of their business models.

M. Wessel and N. Helmer, , MIT Sloan Management Review, March 10, 2020.

The late Clayton Christensens Theory of Interdependence and Modularity holds that when companies develop new technologies, they attempt to manage every aspect of the systems design to optimize performance. For example, Apple initially controlled every part of the iPhones complex system. As the components became standardized, other companies entered the fray to specialize in specific pieces of the system. The internet and other technologies increase modularity in value chains across industries, which enables other businesses to insert themselves into the value chain.

Morally responsible startups develop technology and create ethical benchmarks as if they already dominate the industry. As new developers create products in response to consumer demand in a narrow slice of a system, individuals enjoy the abundance of choice without worrying about the overall negative effect on society. Moreover, the rate of innovation outstrips governments ability to regulate preventively. Thats why the onus of establishing these ethical priorities rests on the innovators.

As an organization, put yourself in the role of standard-bearer, instead of just imagining what you can do to break apart the value chain, Wessel argues. Assuming ethical responsibility for an innovation may decelerate a companys development in the short run but will be a competitive advantage in the long run. Apples attention to privacy protection in its technology may have slowed its progress compared with competitors, but Apple has gained public trust.

Other companies, such as Uber, were late to address certain moral issues but worked to adapt, which arguably helped fend off user backlash.

Create an objective advisory board to review the ethical considerations of your companys activities. Genetic testing firm 23andMe handles possible regulatory and user concerns proactively. Executives created an independent board to review the ethics of the companys activities for example, around its customer data. Such prudence has given 23andMe an edge when dealing with regulatory bodies and made its good intentions more credible for consumers. Taking its responsibility seriously has helped the company create a more solid foundation for future success.

Advisory boards made up of people with different perspectives, backgrounds, and expertise provide guidance on relevant issues and counter the cognitive bias that exists in every organization. In the media industry, for example, established companies such as The New York Times and The Washington Post understand the role they play in society. Relative newcomers building the next generation of communication technology must be aware of the implications of their business models at scale and understand the existing players precautionary measures.

Managements role is crucial. The CEO should provide clear guidance on ethics and infuse those principles into the culture. Dont take shortcuts, even in times of crisis. Google and Apple are stepping up to trace and track infected individuals in response to the COVID-19 crisis, yet they cant disregard privacy considerations, even during a global pandemic.

Takeaways from the session:

Event Notifications

Get periodic email updates on upcoming webinars, panel discussions, and other special events.

Please enter a valid email address

Thank you for signing up

Privacy Policy

Max Wessel (@maxwellelliot) is chief innovation officer at SAP. Karen Dillon (@kardillon) is a former editor of Harvard Business Review, coauthor of three bestselling books with Clayton M. Christensen, and guest editor for MIT SMRs spring 2020 issue. She moderated the session.

Read more from the original source:
Ethics in Technology Innovation: A Live Session at Disruption 2020 - MIT Sloan

Over-the-Counter

The report is a compilation of different studies, including regional analysis where leading regional Direct-To-Consumer (DTC) Genetic Testing markets are comprehensive studied by market experts. Both developed and developing regions and countries are covered in the report for a 360-degree geographic analysis of the Direct-To-Consumer (DTC) Genetic Testing market. The regional analysis section helps readers to become familiar with the growth patterns of important regional Direct-To-Consumer (DTC) Genetic Testing markets. It also provides information on lucrative opportunities available in key regional Direct-To-Consumer (DTC) Genetic Testing markets.

Ask For Discounts, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=248561&utm_source=COD&utm_medium=888

Table of Content

1 Introduction of Direct-To-Consumer (DTC) Genetic Testing Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Direct-To-Consumer (DTC) Genetic Testing Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Direct-To-Consumer (DTC) Genetic Testing Market, By Deployment Model

5.1 Overview

6 Direct-To-Consumer (DTC) Genetic Testing Market, By Solution

6.1 Overview

7 Direct-To-Consumer (DTC) Genetic Testing Market, By Vertical

7.1 Overview

8 Direct-To-Consumer (DTC) Genetic Testing Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Direct-To-Consumer (DTC) Genetic Testing Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report

@ https://www.marketresearchintellect.com/need-customization/?rid=248561&utm_source=COD&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Direct-To-Consumer (DTC) Genetic Testing Market Size, Direct-To-Consumer (DTC) Genetic Testing Market Trends, Direct-To-Consumer (DTC) Genetic Testing Market Growth, Direct-To-Consumer (DTC) Genetic Testing Market Forecast, Direct-To-Consumer (DTC) Genetic Testing Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Read more:
Direct-To-Consumer (DTC) Genetic Testing Market Development, Trends, Key Driven Factors, Segmentation And Forecast to 2020-2026 - Cole of Duty

Telephone-based genetic counseling is just as useful as in-person meetings for those who would like to better understand and potentially reduce their risks of developing cancer, according to research presented May 13 in advance of the American Society of Clinical Oncology's (ASCO) virtual scientific program, to be held May 29 through 31.

The study indicates that remote forms of counseling, including telephone or real-time video to consult with a healthcare professional, can be a highly effective tool to provide preventive cancer care and genetic counseling, say the authors of the study, which was led by MD Anderson Cancer Center in Houston.

The use of remote healthcare services, ortelehealth, has soared in recent months due to the COVID-19 pandemic and the need for healthcare professionals and patients to find ways to communicate without risking transmission of the coronavirus.

The new study, which was performed prior to the pandemic, was designed to assess ways to make genetic testing more accessible and to validate the process of remote testing and counseling.

The study, dubbed MAGENTA (Making Genetic Testing Accessible)), is a national, randomized trial focusing on people at risk for breast cancer and ovarian cancer. Genetic counseling can be particularly helpful to assess the risks of these two cancers because there are identifiable gene mutations known to increase risk, such as the BRCA gene mutations.

More than a dozen other gene mutations including CHEK2, CDH1, andPTEN mutations are known to increase the risk of breast or ovarian cancer or both.

Genetic counseling and, if indicated, testing can help people understand their risk, determine whether other family members are at an increased risk, and trigger medical care to lower risk, such as more frequent cancer screenings, lifestyle changes, use of preventive medication, and even prophylactic surgery.

The study included nearly 4,000 women age 30 and older who had not had genetic counseling or genetic testing in the past and who either had breast or ovarian cancer themselves or had a family member with one of those cancers.

The participants received a genetic test and were assigned to receive either in-person counseling or telephone counseling. Those who received remote counseling received a genetic home test kit, which required providing a saliva sample in a tube and mailing it in.

Among those participants who completed genetic testing, 7.2 percent were found to have a genetic mutation that increased breast or ovarian cancer risk. Researchers reported no changes in the participants levels of anxiety and distress when receiving remote counseling compared with in-person counseling. In fact, those in the telephone counseling group were more likely to follow through with scheduling related medical care compared with those in the in-person counseling group.

The remote testing and education methods resulted in more follow-through in completing the testing than traditional genetic counseling, even though counseling was provided conveniently by phone, saysEElizabeth M. Swisher, MD, director of the Breast and Ovarian Cancer Prevention Program at the Seattle Cancer Care Alliance and coleader of the Stand Up to Cancer Ovarian CancerNational Ovarian Cancer Coalition Dream Team, which sponsored the study.

Our results provide a foundation for electronic access to testing that goes beyond telehealth access, with equivalent patient outcomes less hassle for patients and less cost to the healthcare system, says Dr. Swisher.

RELATED: COVID-19 Warriors: Stories From the Front Lines of the Pandemic

A randomized, phase 2 clinical trial shows that an approach called transoral resection with low-dose radiation is safe and effective for some people with oropharynx (throat) cancer. The approach is easier to tolerate and leaves patients with fewer long-term side effects related to radiation.

The study of 353 people compared several approaches to throat cancer caused by human papillomavirus, which accounts for about 70 percent of the disease, according to the Centers for Disease Control and Prevention. Researchers examined pathological biomarkers unique to each patient, such as the extent of cancer in the lymph nodes and tumor characteristics.

Following surgery using a transoral robotic approach (TORS), people with a low risk of recurrence were observed. Those with an intermediate risk of recurrence received lower-dose radiation. People at a high risk of recurrence were assigned to the standard dose of radiation plus chemotherapy.

The study showed that for intermediate-risk patients, a reduced dose of radiation after surgery without chemotherapy appears sufficient. Less radiation typically preserves a patients throat function and reduces pain, the authors note.

The group receiving a reduced dose of radiation also had better outcomes than the group receiving high-dose radiation plus chemotherapy. People with low-risk disease had low recurrence rates after two years.

The study showed the value of stratifying patients according to risk and that the TORS surgical approach followed by low-dose radiation is safe and effective in people with intermediate-risk, locally advanced throat cancer, says lead investigator Robert L. Ferris, MD, PhD, director of theHillman Cancer Center at the University of Pittsburgh Medical Center and a surgical oncologist specializing in head and neck cancer.

"These results present a promising deintensification approach," he says.

RELATED: How Will COVID-19 Affect Cancer Research?

About 25 percent of all people with cancer taking oral chemotherapy medications also take herbal supplements, according to research from the University of Rhode Island. Assessing the use of over-the-counter herbal supplements is important because some substances may interact with oral chemotherapy agents, the authors say.

The study of 187 people taking oral chemotherapy drugs found that 24 percent were also taking herbal dietary supplements. The most frequently used supplements were melatonin and marijuana orcannabidiol oil. The authors recommend that people taking oral chemotherapy consult with an oncology pharmacist to prevent drug interactions and maximize the effectiveness of oral chemotherapy.

Federal health officials also recommend that people being treated for cancer consult with their healthcare providers before using any complementary health approach, such as using dietary supplements. According to the National Center for Complementary and Integrative Health, only about 15 percent of people being treated for cancer who use herbal supplements discuss their usage with their healthcare providers.

RELATED: Can You Overdose on Melatonin? How to Determine the Right Dosage for You

The combination of Opdivo (nivolumab) and Yervoy (ipilimumab) with limited chemotherapy appears to prolong overall survival as a first-line treatment for people with metastatic non-small cell lung cancer (NSCLC). The study suggests that adding limited chemotherapy to the combination of Opdivo and Yervoy may reduce the risk of the disease progressing when its in the early stage.

A previous study, CheckMate-227, showed the value of the immunotherapy combination as a first-line treatment for NSCLC. Opdivo is a type of immunotherapy known as a PD-1 inhibitor, while Yervoy is a category of drug known as a CTLA-4 inhibitor.

The new study, called CheckMate-9LA, was designed to assess the value of adding chemotherapy to the combination. The research presented at ASCO is the first release of results from CheckMate-9LA.

The phase 3 trial showed that Opdivo and Yervoy given together with two cycles of chemotherapy reduced the risk of death by 31 percent compared with chemotherapy alone after at least eight months of follow-up. After more than a year of follow-up, the combination plus chemotherapy showed continued improvements in overall survival compared with chemotherapy alone.

Adding a limited course of chemotherapy may help mitigate the risk of early disease progression, saysMartin Reck, MD, PhD, the studys lead investigator and an oncologist at the Lung Clinic Grosshansdorf in Germany. As the data become more mature, I see the potential for an improving survival benefit over time.

RELATED: Smokers Who Quit Before Lung Cancer Diagnosis Are More Likely to Survive the Disease

See the original post:
Genetic Counseling, New Treatments for Lung Cancer and Throat Cancer, and More From ASCO's Annual Meeting - Everyday Health

Magnifier Research has recently published a research report titled Global DTC Genetic Testing Market Size, Status and Forecast 2020-2026 explores the ongoing outlook in global and key regions from the perspective of major players, countries, product types and end industries. The report comprises and forecast values for a versatile understanding. Then, the report offers the perspective of major players, countries, product types and end industries. The research also analyzes top players in the global market and divides the market into several parameters. It presents the profile reviews of the leading participants, their overall market shares in the global DTC Genetic Testing market, business strategies they have adopted, and the latest developments in their respective businesses.

Market Analysis:

The report gives an evaluation of various drivers, technological innovations, upcoming technologies, opportunities, market risks, restraints, market barriers, challenges, trends, competitive landscape, and segments. The report analyzes the scope of different segments and applications that can potentially influence the global DTC Genetic Testing market in the future. Diverse topics discovered in the report includes regional market scope, product-market various applications, market size according to a specific product, sales, and revenue by region, production cost analysis, supply chain, market influencing factors analysis, market size estimates, a look at the target market, an analysis of competition.

DOWNLOAD FREE SAMPLE REPORT: https://www.magnifierresearch.com/report-detail/29799/request-sample

Major key players of the market are: 23andMe, Ancestry, Color, EasyDNA, Family Tree DNAGene by Gene, Full Genomes, Genesis HealthCare, Helix, Identigene, Karmagenes, Living DNA, MapMyGenome, MyHeritage, Pathway Genomics,

For a comprehensive understanding of market dynamics, the market is analyzed across key geographies namely: North America (United States, Canada, Mexico), Asia-Pacific (China, Japan, South Korea, India, Australia, Indonesia, Thailand, Malaysia, Philippines, Vietnam), Europe (Germany, France, UK, Italy, Russia, Rest of Europe), Central & South America (Brazil, Rest of South America), Middle East & Africa (GCC Countries, Turkey, Egypt, South Africa, Rest of Middle East & Africa)

This report segments the global market on the basis of types are:

On the basis of application, the global market is segmented into: Carrier Testing, Predictive Testing, Ancestry and Relationship Testing, Nutrigenomics Testing, Other

Furthermore, the global DTC Genetic Testing research report has mentioned key manufacturers strategic enterprises and provides a brief about their structure. Analysts have also mentioned the research and development conditions of these companies and their provided complete information about their existing products. The report has figured out key factors as per segments and it includes price, value, availability, features, financing, upgrades or returns policies, and customer service. Most noteworthy, this market analysis will help you find market dark spots in the market.

ACCESS FULL REPORT: https://www.magnifierresearch.com/report/global-dtc-genetic-testing-market-size-status-and-29799.html

Projections:

The report offers thoughtful forecasting. It also explains the consumption behaviour of users. Here, analysts have shown real stats and numbers. These bottom-up projections will explain how your marketing and sales efforts will enable you to get a certain percentage of the market. This report study describes the projected growth of the global DTC Genetic Testing market for approaching years from 2020 to 2026.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@magnifierresearch.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Magnifier Research is a leading market intelligence company that sells reports of top publishers in the technology industry. Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Magnifier Research also specializes in analyzing hi-tech systems and current processing systems in its expertise. We have a team of experts that compile precise research reports and actively advise top companies to improve their existing processes. Our experts have extensive experience in the topics that they cover. Magnifier Research provides you the full spectrum of services related to market research, and corroborate with the clients to increase the revenue stream, and address process gaps.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@magnifierresearch.comWeb: http://www.magnifierresearch.com

Read more here:
COVID-19 IMPACT ON DTC Genetic Testing Market | VOLUME, ANALYSIS, FUTURE PREDICTION, INDUSTRY OVERVIEW AND FORECAST 2026 - Surfacing Magazine

In recent years it has become clear that a persons genetic makeup has a strong influence on body weight and how they respond to different foods and exercises.

With scientific advances, information in DNA can be used to predict which diets, lifestyle choices and exercise work best for each individual person.

Aoife Ni Eochaidh, gene tester, offers a simple, saliva-based test for men and women which analyses over 110 genetic variations that influence how persons respond to diet and exercise. These genes have been selected based on hundreds of studies.

Each test report comes with a comprehensive guide that includes a user friendly index of your DNA analysis and detailed nutritional, lifestyle and exercise recommendations. This test is a powerful tool that enables Aoife to guide you on your path to an optimal diet, lifestyle and exercise choices. Whether you are looking to lose weight, get fitter or improve your health and diet in the most optimum way for you, let your Genes predict the best options.

Further information please contact Aoife on 087 2863013 or email [emailprotected].

Continued here:
Personalise your health and fitness with genetic testing - Galway Advertiser

Progenesis

Preimplantation Genetic Testing Market Competitive Analysis:

In addition, the projections offered in this report were derived using proven research assumptions and methods. In this way, the Preimplantation Genetic Testing research study offers a collection of information and analysis for every facet of the Preimplantation Genetic Testing market such as technology, regional markets, applications and types. The Preimplantation Genetic Testing market report also offers some market presentations and illustrations that include pie charts, diagrams and charts that show the percentage of different strategies implemented by service providers in the Preimplantation Genetic Testing market. In addition, the report was created using complete surveys, primary research interviews, observations and secondary research.

In addition, the Preimplantation Genetic Testing market report introduced the market through various factors such as classifications, definitions, market overview, product specifications, cost structures, manufacturing processes, raw materials and applications. This report also provides key data on SWOT analysis, return data for investments and feasibility analysis for investments. The Preimplantation Genetic Testing market study also highlights the extremely lucrative market opportunities that are influencing the growth of the global market. In addition, the study offers a complete analysis of market size, segmentation and market share. In addition, the Preimplantation Genetic Testing report contains market dynamics such as market restrictions, growth drivers, opportunities, service providers, stakeholders, investors, important market participants, profile assessment and challenges of the global market.

Preimplantation Genetic Testing Market Segments:

The report also underscores their strategics planning including mergers, acquisitions, ventures, partnerships, product launches, and brand developments. Additionally, the report renders the exhaustive analysis of crucial market segments, which includes Preimplantation Genetic Testing types, applications, and regions. The segmentation sections cover analytical and forecast details of each segment based on their profitability, global demand, current revue, and development prospects. The report further scrutinizes diverse regions including North America, Asia Pacific, Europe, Middle East, and Africa, and South America. The report eventually helps clients in driving their Preimplantation Genetic Testing business wisely and building superior strategies for their Preimplantation Genetic Testing businesses.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24037&utm_source=COD&utm_medium=003

Table of Content

1 Introduction of Preimplantation Genetic Testing Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Preimplantation Genetic Testing Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Preimplantation Genetic Testing Market, By Deployment Model

5.1 Overview

6 Preimplantation Genetic Testing Market, By Solution

6.1 Overview

7 Preimplantation Genetic Testing Market, By Vertical

7.1 Overview

8 Preimplantation Genetic Testing Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Preimplantation Genetic Testing Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report @ https://www.verifiedmarketresearch.com/product/Preimplantation-Genetic-Testing-Market/?utm_source=COD&utm_medium=003

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defence, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Tags: Preimplantation Genetic Testing Market Size, Preimplantation Genetic Testing Market Trends, Preimplantation Genetic Testing Market Growth, Preimplantation Genetic Testing Market Forecast, Preimplantation Genetic Testing Market Analysis NMK, Majhi Naukri, Sarkari Naukri, Sarkari Result

Our Trending Reports

Cellular Health Screening-Health Testing Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Preimplantation Genetic Testing Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See the original post:
Preimplantation Genetic Testing Market Research Report 2020 By Size, Share, Trends, Analysis and Forecast to 2026 - Cole of Duty

Global Animal Genetic Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global animal genetics market for Global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

Global Animal Genetic Marketis expected to rise from its estimated value of USD 4.39 billion in 2018 to an estimated value of USD 8.68 billion by 2026 registering a CAGR of 8.9% in the forecast period of 2019-2026.The upcoming market report contains data for historic years 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.Few of the major market competitors currently working in the animal genetics market areNEOGEN CORPORATION, Zoetis, Envigo, Animal Genetics Inc., VetGen, Groupe Grimaud, Hendrix Genetics BV, EW Nutrition GmbH, Alta Genetics Inc., Genus, Topigs Norsvin, CRV Holding B.V., URUS, Trans Ova Genetics., Inguran LLC dba STgenetics., Semex, Beacon Automation Pty Ltd., Cogent, EVOLUTION International , Genex Services, LLC, Rockway, Inc., River Valley Dairy., ABS GLOBAL, INC., Anicam Enterprises Inc., Milk Source. among others

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-animal-genetics-market

Global Animal Genetic Market By Product (Live Animals (Poultry, Porcine, Bovines, Canine, Others), Genetic Material (Semens, Embroys)), Genetic Testing Services (DNA typing, genetic trait tests, genetic disease tests, and others), Geography (North America, South America, Europe, Asia-Pacific and Middle East and Africa) Industry Trends & Forecast to 2026;

Market Definition: Global Animal Genetic Market

Animal genetics is the branch of science which deals with the study of inheritance and gene variation in domestic and wild animals. Animal genetics are mostly used for genetic trait testing, DNA testing, and genetic disease traiting. The animal genetics market is expected to increase due to the fast demand, ingesting of animal proteins, and surge in urban population, which shows demand for meat products across the globe during the forecast period.

Market Drivers

Market Restraints

Grab Your Report at an Impressive 30% Discount! Please click [emailprotected]https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-animal-genetics-market

Segmentation: Global Animal Genetic Market

By Product

By Genetic Testing Services

Key Developments in the Market:

Reasons to Purchase this Report

Customization of the Report:

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Excerpt from:
Animal Genetic Market 2020: Industry Analysis and Detailed Profiles of Top Industry Players 3w Market News Reports - 3rd Watch News

The coronavirus, as we all know, has brought our economy to its knees. As the search for vaccines and treatments accelerates, geneticists are now looking to our genes to understand why some recover quickly or show no symptoms, while others die. To do so, they are searching DNA databases and cross-referencing them with COVID-19 cases. This research holds great promise for addressing the pandemic.

Yet if scientists do find answers in our genes, we need to consider the implications for genetic privacy. Armed with the ability to identify who is vulnerable and who is not, how will society proceed?

On the one hand, health care providers could use genetic testing to help vulnerable patients stay safe. But there would also be a temptation to use genetic testing in the workplace. Companies could use genetic test results to manage the risks for all employees, for example by controlling the activities of those who are most vulnerable. Businesses will also see opportunities to use genetic test results in the marketplace, for example by tailoring insurance offerings according to genetic risk. Currently, there are some limited legal protections against genetic discrimination and health privacy intrusions, but the pandemic has already led the federal government toscale backsome of those protections for the time being.

Although the rationale for expanded genetic testing is obviously meant for the greater good, such testing could also bring with it a host of privacy and economic harms. In the past, genetic testing has also been associated with employment discrimination. Even before the current crisis, companies like 23andMe and Ancestry assembled and started operating their own private long-term large-scale databases of U.S. citizens genetic and health data. 23andMe and Ancestry recently announced they would use their databases to identify genetic factors that predict COVID-19 susceptibility.

Other companies are growing similar databases, for a range of purposes. And the NIHs AllofUs program is constructing a genetic database, owned by the federal government, in which data from one million people will be used to study various diseases. These new developments indicate an urgent need for appropriate genetic data governance.

Leaders from the biomedical research community recently proposed a voluntary code of conduct for organizations constructing and sharing genetic databases. We believe that the public has a right to understand the risks of genetic databases and a right to have a say in how those databases will be governed. To ascertain public expectations about genetic data governance, we surveyed over two thousand (n=2,020) individuals who altogether are representative of the general U.S. population. After educating respondents about the key benefits and risks associated with DNA databasesusing information from recent mainstream news reportswe asked how willing they would be to provide their DNA data for such a database.

The results were surprising. Initially, we believed people would generally approve of donating their genetic data for altruistic reasons, such as for example, finding a vaccine for COVID-19, so we assumed they would be more willing to provide their data to a hospital or university compared with a tech company or pharmaceutical firm. But we found a fairly similar level of willingnessregardless of who owns the database. While 37 percent were unwilling to provide their DNA data to a technology company (like 23andMe), about the same percent were unwilling to provide it to a hospital (40 percent), a government health institute (37 percent), a pharmaceutical firm (40 percent) or a university (35 percent).

The most important thing our survey revealed was that the willingness of individuals to provide their genetic data depended greatly on the kinds of policies that would govern that data. Thus, in order to find a vaccine for COVID-19, we must have genetic data governance policies that inspire confidence and that will prompt the public to donate their genetic data. Willingness to provide genetic data increased the most when people were told they would have the ability to control how their stored data is reused or shared in the future. This willingness also increased when people were assured they could have their data deleted at any point.

Conversely, one of the policies that reduced willingness to contribute the most was the retention of data indefinitely without a specified date for destruction. These patterns held equally among people who were willing to provide their data as an altruistic donation and people who were only willing to provide their data in exchange for payment of some kind. The patterns also held regardless of the type of organization the respondent was being asked about, that is whether tech company, hospital, government, pharmaceutical firm or university.

Not surprisingly, we also found that willingness to provide genetic data increased greatly when contributors knew that the organization would be using state-of-the-art cybersecurity to protect their data.

Together, these findings indicate two principles to guide needed regulation and any code of conduct for genetic databases.

The first is personal agency and control. People want to know that they can control the end uses of their DNA data. This principle puts the burden on database owners to obtain additional permissions when they want to reuse or share data. It also means designing databases so each entry has an expiration date and can be selectively removed. Technologies exist to support this principle, and some organizations are using them.

The second is equal treatment of all organizations. The same rules should apply regardless of an organizations sector (e.g., for-profit, nonprofit, government); industry (health care, technology, consumer/lifestyle and so on); or size. Such distinctions make little sense in an era when data are routinely moved, shared and reused across organizations, sectors and industriesoftenwithout the full understanding of the peopleincluded in the data.

How can these principles be integrated with existing law and regulation? One approach would be to treat genetic sequence data as personal health information under HIPAA. This is consistent with the current understanding that genetic data can neither be truly de-identified nor completely stripped of sensitive informational content. Organizational policies for data access and cybersecurity can then follow health sector guidelines at a minimum.

Naturally, when biomedical researchers think about rules for genetic information databases, they want to avoid excessive limits on using the data. After all, such limits may slow scientific progress and reduce the societal benefits of the databases. But as suggested by the recent consumer genetics slowdown, without appropriate rules in place, the public may become wary of participating. Thus, it is imperative to consider public opinion of genetic data collection, the safeguarding of the data, and the use of DNA databases.

Our research suggestsour proposed principles for genetic database governance will help preserve the publics willingness to contribute their genetic informationwhich may be our only hope of defeating the coronavirus.

The authors are co-principal investigators on a grant by the Robert Wood Johnson Foundation to research the governance of genetic testing as part of corporate wellness programs. Their article Evolving public views on the value of ones DNA and expectations for genomic database governance: Results from a national survey, co-authored with Allison Gaddis and Jennifer McCormick, was published by PLOS ONE.

Read more about the coronavirus outbreak from Scientific American here, and read coverage from our international network of magazines here.

Here is the original post:
The Answer to a COVID-19 Vaccine May Lie in Our Genes, But ... - Scientific American

COLUMBIA, Md., May 15, 2020 /PRNewswire/ -- The Foundation Fighting Blindness, the world's leading organization searching for treatments and cures for inherited retinal diseases, has introduced many improvements and upgrades to its My Retina Tracker Registry. Overall, the upgraded platform makes this best-in-class patient database even easier to use for patients, industry, and investigators who access de-identified data for research studies and clinical trial recruitment. Launched in 2013, more than 15,500 IRD patients are active in the Registry. The patient-driven registry is accessible at MyRetinaTracker.org.

"The My Retina Tracker Registry has been an invaluable resource for both IRD patients and research communities. It provides a secure venue for patients to get on the radar screens of therapy developers both industry and researcher partners who are recruiting for clinical trials and conducting studies using human data," says Brian Mansfield, PhD, executive vice president of research and interim chief scientific officer. "From the start, we have been strongly committed to security of privacy coupled with ease-of-use for both patients and professionals. These enhancements are part of our continual process to maximize the registry's usability and efficiently integrate it with our genetic testing programs."

Highlights of upgrades and enhancements:

The Foundation also offers no-cost genetic testing for those affected with IRDs. The Open Access Genetic Testing Program, allows for any eye care professional in the U.S. to order the no-cost test along with a no-cost genetic counseling session for their IRD patients. Neither membership to My Retina Tracker Registry, nor clinician pre-approval, is needed to participate in the Open Access Genetic Testing Program and receive free testing and genetic counseling.

If a person who is tested chooses to join My Retina Tracker Registry, their data is automatically uploaded into their profile from the genetic testing laboratory.

Current sponsors of the new My Retina Tracker Registry include: The George Gund Foundation, Eloxx Pharmaceuticals, Sofia Sees Hope, AGTC and MeiraGTx. Sponsors of the Open Access Genetic Testing Program include: ProQR, Blueprint Genetics, InformedDNA, Sophia Sees Hope, and The George Gund Foundation.

About the Foundation Fighting BlindnessEstablished in 1971, the Foundation Fighting Blindness is the world's leading private funding source for retinal degenerative disease research. The Foundation has raised more than $760 million toward its mission of accelerating research for preventing, treating, and curing blindness caused by the entire spectrum of retinal degenerative diseases including: retinitis pigmentosa, age-related macular degeneration, Usher syndrome, and Stargardt disease. VisitFightingBlindness.orgfor more information.

Media Contact:Chris AdamsVice President, Marketing & Communicationscadams@fightingblindness.org410-423-0585

See the article here:
Foundation Fighting Blindness Launches Upgraded My Retina Tracker Registry for People with Inherited Retinal Diseases (IRDs) - Herald-Mail Media

In the season premiere of actressCourteney Coxs Facebook Watch Series Nine Months WithCourteney Cox, she opens up about her experience discovering she had aMTHFR gene mutation. Not only does this mutation make pregnancy difficult, but it also increases risk of types of cancer which is why genetic testing is crucial for everyone.

In her Facebook Watch stream, Cox, 55, revealed that she had suffered miscarriages in the past and four years ago discovered that it was due toMTHFR gene mutation. According to a study from theNational Center for Biotechnology Information (NCBI), this gene mutation also increases the risk of breast cancer as well as ovarian cancer. Additionally, Coxs father, Richard Lewis Cox, passed away after battling cancer in 2001.

Related:Sadness Is Not Always A Bad Thing Coping After Losing A Parent To Cancer

About four years ago, I found out I have something called a MTHFR gene mutation, which dictates how my body methylates, Cox explained in the video. I suffered miscarriages, my dad died of a really rare cancer, and depression runs in my family, which made my doctor think I should get this gene checked out. I discovered that I have the worst version of the mutation and my body doesnt methylate the way its supposed to.

For many people, genetic testing is a crucial step in understanding whether youre more or less at risk for a cancer diagnosis. Some specific gene mutations are directly linked to types of cancers, and by going through genetic testing, doctors will be able to identify these mutations in people. This is especially the case when it comes to ovarian cancer, which is linked toBRCA-1 and BRCA-2 gene defects.

Dr. Kellie Schneider explains why genetic testing is important to detect ovarian cancer

Genetic testing is important for several different reasons,Dr.Kellie Schneider, a gynecologic oncologist at Novant Health in Charlotte, North Carolina, tells SurvivorNet. Ovarian cancer is a relatively rare cancer so when we see it in a patient we worry theres something that put them genetically at risk for that cancer.We would want to know for their sake and their familys sake if we need to be screening for any additional cancers once they are in remission from their ovarian cancer.

Related: Ovarian Cancer: Understanding the Different Categories of Genetic Testing- What You Got From Your Parents & Whats Changed Since You Were Born

Genetic testing cannot only help a possible patient, but also their family members. Breast cancer survivor Amy Armstrong talked to SurvivorNet about why she got genetically tested for stomach cancer, which runs in her family.

[My mom] uncovered that she had a very rare stomach cancer gene called CDH1, Amy said. If you have this gene, not only is it incredibly rare, but youre also confronted [with] making a pretty big decision to avoid getting stomach cancer. You have to have a prophylactic gastrectomy. When my mom found out that she had the gene, it had a domino effect for not only her siblings to be tested for the gene, but also her children and 3 out of 4 of us, my siblings, tested positive for the gene.

According to Armstrong, CDH1 is a dominant gene so theres a 50/50 chance of passing it on to a child. In order to avoid passing this gene to her family, she underwent a prophylactic gastrectomy (stomach removal) to reduce her chance of getting cancer.

Breast cancer survivor Amy Armstrong shares why she went through genetic testing

Learn more about SurvivorNet's rigorous medical review process.

In the season premiere of actressCourteney Coxs Facebook Watch Series Nine Months WithCourteney Cox, she opens up about her experience discovering she had aMTHFR gene mutation. Not only does this mutation make pregnancy difficult, but it also increases risk of types of cancer which is why genetic testing is crucial for everyone.

In her Facebook Watch stream, Cox, 55, revealed that she had suffered miscarriages in the past and four years ago discovered that it was due toMTHFR gene mutation. According to a study from theNational Center for Biotechnology Information (NCBI), this gene mutation also increases the risk of breast cancer as well as ovarian cancer. Additionally, Coxs father, Richard Lewis Cox, passed away after battling cancer in 2001.

About four years ago, I found out I have something called a MTHFR gene mutation, which dictates how my body methylates, Cox explained in the video. I suffered miscarriages, my dad died of a really rare cancer, and depression runs in my family, which made my doctor think I should get this gene checked out. I discovered that I have the worst version of the mutation and my body doesnt methylate the way its supposed to.

For many people, genetic testing is a crucial step in understanding whether youre more or less at risk for a cancer diagnosis. Some specific gene mutations are directly linked to types of cancers, and by going through genetic testing, doctors will be able to identify these mutations in people. This is especially the case when it comes to ovarian cancer, which is linked toBRCA-1 and BRCA-2 gene defects.

Dr. Kellie Schneider explains why genetic testing is important to detect ovarian cancer

Genetic testing is important for several different reasons,Dr.Kellie Schneider, a gynecologic oncologist at Novant Health in Charlotte, North Carolina, tells SurvivorNet. Ovarian cancer is a relatively rare cancer so when we see it in a patient we worry theres something that put them genetically at risk for that cancer.We would want to know for their sake and their familys sake if we need to be screening for any additional cancers once they are in remission from their ovarian cancer.

Related: Ovarian Cancer: Understanding the Different Categories of Genetic Testing- What You Got From Your Parents & Whats Changed Since You Were Born

Genetic testing cannot only help a possible patient, but also their family members. Breast cancer survivor Amy Armstrong talked to SurvivorNet about why she got genetically tested for stomach cancer, which runs in her family.

[My mom] uncovered that she had a very rare stomach cancer gene called CDH1, Amy said. If you have this gene, not only is it incredibly rare, but youre also confronted [with] making a pretty big decision to avoid getting stomach cancer. You have to have a prophylactic gastrectomy. When my mom found out that she had the gene, it had a domino effect for not only her siblings to be tested for the gene, but also her children and 3 out of 4 of us, my siblings, tested positive for the gene.

According to Armstrong, CDH1 is a dominant gene so theres a 50/50 chance of passing it on to a child. In order to avoid passing this gene to her family, she underwent a prophylactic gastrectomy (stomach removal) to reduce her chance of getting cancer.

Breast cancer survivor Amy Armstrong shares why she went through genetic testing

Learn more about SurvivorNet's rigorous medical review process.

Here is the original post:
Actress Courteney Cox Says MTHFR Gene Mutation Made Pregnancy Difficult The Importance Of Genetic Testing To Detect Cancer Risk - SurvivorNet